


Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0045 161
A1

⑫

EUROPEAN PATENT APPLICATION

⑰ Application number: 81303270.3

⑱ Date of filing: 16.07.81

②① Int. Cl.³: **C 07 C 103/50**, C 07 C 103/84,
 C 07 D 207/16, C 07 D 277/06,
 C 07 D 279/06, C 07 D 265/06,
 C 07 D 239/04, C 07 D 307/32,
 C 07 D 209/20

⑳ Priority: 24.07.80 GB 8024305
 24.11.80 GB 8037651

㉑ Date of publication of application: 03.02.82
 Bulletin 82/5

㉒ Designated Contracting States: AT BE CH DE FR GB IT
 LI LU NL SE


㉓ Applicant: **IMPERIAL CHEMICAL INDUSTRIES PLC**,
 Imperial Chemical House Millbank, London SW1P 3JF
 (GB)

㉔ Inventor: **Gravestock, Michael Barry**, 10 Dawlish Avenue
 Cheadle Hulme, Cheadle Cheshire SK8 6JF (GB)

㉕ Representative: **Slatcher, Reginald Peter et al**, Imperial
 Chemical Industries PLC Legal Department: Patents
 Thames House North Millbank, London SW1P 4QG (GB)

㉖ Amides of 4-oxo-5-amidohexanoic acid derivatives.

㉗ The invention concerns novel amide derivatives of the formula:




wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^{10}, R^{11}$ and R^{16} are various substituents defined hereinafter, Y is carbonyl, thiocarbonyl, sulphonyl or amido, X is carbonyl, hydroxymethylene, thiocarbonyl or oximinomethylene and Q is carbonyl or methylene, or a salt thereof, which are inhibitors of angiotensin converting enzyme and may be used for example, in the treatment of hypertension. The invention also provides pharmaceutical compositions of and processes for the manufacture of the novel amide derivatives.

EP 0 045 161 A1


AMIDES OF 4-OXO-5-AMIDOHENANOIC ACID DERIVATIVES

This invention relates to new amide derivatives and more particularly it relates to amide derivatives which are inhibitors of angiotensin converting enzyme (hereinafter ACE).

5 Various inhibitors of ACE are known. One is commercially available under the name captopril and has the chemical structure:-




10 Another, known as MK 421, is at an advanced stage of clinical trial and this has the chemical structure:-



15 Various analogues of these compounds are described in the literature, especially in patent specifications. No ACE inhibitor is known, however, which bears a ketonic group in the chemical structure, and there are now herein for the first time provided such compounds.

According to the invention there is provided an amide derivative of the formula:-



wherein either R^1 is hydrogen, or alkyl of up to 15 carbon atoms which is unsubstituted, or which bears one substituent selected from amino, benzyloxycarbonyl-amino, hydroxy, alkoxy, alkylthio and alkoxy carbonyl

5 each of up to 5 carbon atoms, and aryl, aryloxy and arylthio substituents; or which bears two or three substituents one of which is aryl, another of which is aryl, hydroxy, amino, benzyloxycarbonylamino, trifluoromethyl, aryloxy or alkoxy of up to 5 carbon atoms and the

10 third of which, if present, is aryl or trifluoromethyl; or R^1 is aryl or, when Y is carbonyl or thio-carbonyl, is aryloxy, alkoxy or arylalkoxy wherein the alkoxy part has up to 5 carbon atoms;

or R^1 is halogenoalkyl of up to 6 carbon atoms

15 or is alkenyl, halogenoalkenyl or cycloalkyl each of up to 6 carbon atoms which is unsubstituted or which bears an aryl substituent;

or R^1 is a substituent of the formula $R^8CONHCHR^9-$ or $R^8COCH_2CHR^9-$ wherein R^8 is alkyl or

20 cycloalkyl each of up to 10 carbon atoms, or aryl and R^9 is hydrogen, or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^9 is a group other than those stated above such that the compound H_2NCHR^9COOH would be a common amino acid;

25 wherein R^2 is hydrogen, alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or aryl;

wherein R^3 is alkyl or alkenyl each of up to 5 carbon

30 atoms which is unsubstituted or which bears an aryl substituent, or R^3 is aryl or indolylmethyl;

wherein R^4 is hydrogen or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent;

wherein either R^5 is hydrogen or aryl, or alkyl of up

35 to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^5 is joined together with R^6 as defined below;

wherein either R^6 is hydrogen, aryl or heterocyclic, or alkyl of up to 5 carbon atoms which is unsubstituted or which bears a hydroxy, aryl or heterocyclic substituent;

5 or R^6 and R^5 are joined together to form alkylene or alkenylene of 2 to 5 carbon atoms; or an oxa, thia or aza-derivative of said alkylene or alkenylene; or a hydroxy-or oxo-substituted derivative of said alkylene or alkenylene; or R^6 and R^{16} , or R^6 ,
10 R^{16} and R^5 , or R^6 and R^{10} are joined together as defined below;

 wherein R^{16} is hydrogen or alkyl of up to 5 carbon atoms;

 or R^6 and R^{16} are joined together to form
15 alkylene of 2 to 5 carbon atoms (that is, to form a spirocycloalkyl group);

 or R^{16} together with the first carbon atom of R^6 form a double bond wherein R^6 is otherwise alkyl, or wherein R^6 is otherwise substituted alkyl as
20 defined above, or wherein R^6 and R^5 are otherwise joined together as defined above (that is, so that R^5 , R^6 and R^{16} together form alkylidene);

 wherein Q is carbonyl (-CO-) or methylene (-CH₂-);

 and wherein either R^{10} is hydroxy, amino,
25 aryloxy, arylthio, alkoxy, cycloalkoxy, alkylamino, dialkylamino, cyclic amino, hydroxyalkoxy, acyloxyalkoxy, aminoalkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, cyclic aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, dialkylaminoalkylamino, cyclic aminoalkylamino or aryl-
30 alkoxy wherein each alkyl or alkoxy has up to 5 carbon atoms and wherein cyclic amino has up to 6 carbon atoms;

 or wherein R^{10} and R^6 are joined together such that R^{10} is oxygen (-O-) joined to the terminal carbon atom of R^6 when it is alkyl;

wherein R^{11} is hydrogen or alkyl of up to 3 carbon atoms;

wherein X is carbonyl (-CO-), hydroxymethylene (-CHOH-), thiocarbonyl (-CS-) or oximinomethylene (-C=N-OR²⁰, wherein R²⁰ is hydrogen or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent);

and wherein Y is carbonyl, thiocarbonyl, sulphonyl (-SO₂-) or amido (-NHCO-);

10 or a salt thereof where appropriate.

It will be observed that there are various potentially asymmetrical carbon atoms in the amide of the invention, in particular the carbon atoms which bear the substituents R³, R⁴ and R¹¹ when these substituents are other than hydrogen, and the carbon atom which bears the substituents R⁶ and R¹⁶ when these are different one from the other, and that the amide may therefore exist in racemic and optically active forms. It is to be understood that this invention encompasses the racemic form and any optically-active form which possesses ACE-inhibiting properties, it being a matter of common general knowledge how an optically active compound may be prepared and how the ACE-inhibiting properties of a compound may be measured.

25 A suitable value for R¹ or R⁸ when it is alkyl is, for example, methyl, isobutyl or n-tridecyl.

A suitable value for R², R³, R⁴, R⁵, R⁶, R⁹, R¹⁶ or R²⁰ when it is alkyl is, for example, methyl, ethyl, n-propyl or isobutyl.

30 A suitable value for R¹¹ when it is alkyl is, for example, methyl or ethyl.


A suitable value for R¹ or R¹⁰ when it is alkoxy, or for the alkoxy substituent in R¹ when said group is alkyl substituted by alkoxy is, for example, methoxy, ethoxy or t-butoxy.

A suitable value for R^1 or R^3 when it is alkenyl, is, for example, allyl or 2-methylprop-2-enyl.

A suitable value for R^1 or R^8 when it is cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl.

A suitable value for R^1 , R^2 , R^3 , R^5 , R^6 or R^8 when it is aryl, or for the aryl substituent in the group R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^9 or R^{10} when said group is alkyl substituted by aryl, or for the aryl substituent in R^1 when said group is alkenyl, halogenoalkenyl or cycloalkyl substituted by aryl, or for the aryl substituent in R^3 when said group is alkenyl substituted by aryl, or for the aryl substituent in R^1 or R^{10} when it is aryl-alkoxy, that is, alkoxy substituted by aryl, is, for example, unsubstituted phenyl or naphthyl, or phenyl or naphthyl substituted by one or more substituents selected from halogen, for example fluorine, chlorine, bromine and iodine, alkyl, alkenyl, alkynyl, alkylthio and alkoxy each of up to 5 carbon atoms, for example methyl, ethyl, t-butyl, allyl, propargyl, methylthio, methoxy and ethoxy, and hydroxy, methylenedioxy, amino, nitro, cyano, carboxy, carbamoyl, trifluoromethoxy and trifluoromethyl, aryl, for example phenyl and p-chlorophenyl, and substituents of the formula

25



wherein either R^{30} and R^{31} , which may be the same or different, each is phenyl, or trifluoromethyl, or alkyl of up to 5 carbon atoms, for example methyl, ethyl or n-propyl, which is unsubstituted or which is substituted by phenyl, or R^{30} and R^{31} are joined such that together with the adjacent nitrogen atom they form pyrrolidino, carboxypyrrolidino, alkoxycarbonylpyrrolidino, piperidino, 4-methylpiperazino or morpholino, and wherein -alk- is alkylene of 1 to 4 carbon atoms.

10 A suitable value for R^1 or R^{10} when it is aryloxy, or for the aryloxy substituent in R^1 when R^1 is alkyl substituted by aryloxy, is, for example, unsubstituted phenoxy or phenoxy substituted by one or more substituents selected from those stated above as
15 suitable substituents in aryl.

 A suitable value for R^{10} when it is arylthio, or for the arylthio substituent in R^1 when R^1 is alkyl substituted by arylthio is, for example, unsubstituted phenylthio or phenylthio substituted by one or more
20 substituents selected from those stated in the penultimate paragraph as possible substituents in aryl.

 A suitable value for the alkylthio or alkoxy-carbonyl substituent in R^1 when it is alkyl substituted by alkylthio or alkoxycarbonyl is, for example, methyl-
25 thio or ethoxycarbonyl.

 A suitable value for R^1 when it is halogeno-alkyl or halogenoalkenyl is, for example, trifluoromethyl or 1-chlorovinyl.

 A suitable value for R^6 when it is hetero-
30 cyclic, or for the heterocyclic substituent in R^6 when it

is alkyl substituted by heterocyclic, is, for example indolyl.

- A suitable value for alkylene or alkenylene formed by R^5 and R^6 joined together is, for example, ethylene, trimethylene, 5 tetramethylene, pentamethylene, propenylene ($-\text{CH}_2-\text{CH}=\text{CH}-$), but-1-enylene ($-\text{CH}_2\text{CH}_2-\text{CH}=\text{CH}-$), 2-oxatrimethylene ($-\text{CH}_2-\text{O}-\text{CH}_2-$), 2-thiatrimethylene ($-\text{CH}_2-\text{S}-\text{CH}_2-$), 3-oxa-tetramethylene ($-\text{CH}_2\text{CH}_2-\text{O}-\text{CH}_2-$), 3-thiatetramethylene ($-\text{CH}_2\text{CH}_2-\text{S}-\text{CH}_2-$), 3-azatetramethylene ($-\text{CH}_2\text{CH}_2-\text{NH}-\text{CH}_2-$), 10 3-methyl-3-azatetramethylene ($-\text{CH}_2\text{CH}_2-\overset{\text{CH}_3}{\underset{|}{\text{N}}}-\text{CH}_2-$), 2-hydroxy-trimethylene ($-\text{CH}_2\text{CHOHCH}_2-$), 1-oxotrimethylene ($-\text{COCH}_2\text{CH}_2-$) or 1-oxotetramethylene ($-\text{COCH}_2\text{CH}_2\text{CH}_2-$).

- A suitable value for alkylene formed by R^6 and R^{16} joined together, is, for example ethylene, trimethylene 15 or tetramethylene.

A suitable value for alkylidene formed by R^5 , R^6 and R^{16} joined together is, for example, propan-1-yl-3-ylidene ($-\text{CH}_2\text{CH}_2\text{CH}=\text{}$).

- A suitable value for R^9 when it is a group 20 derived from a common amino acid is, for example, 3-aminopropyl (from L-ornithine), 4-aminobutyl (from L-lysine), hydroxymethyl (from L-serine), α -hydroxyethyl (from L-threonine), β -hydroxyethyl (from L-homoserine), mercaptomethyl (from L-cysteine), β -methylthioethyl 25 (from L-methionine), 3-guanidinopropyl (from L-arginine), imidazol-4-ylmethyl (from L-histidine), carboxymethyl (from L-aspartic acid) or 2-carboxyethyl (from glutamic acid).

- A suitable value for R^{10} when it is cyclo- 30 alkoxy, hydroxyalkoxy or acyloxyalkoxy is, for example, cyclopentyloxy, cyclohexyloxy, 2-hydroxyethoxy, 3-hydroxypropoxy or pivaloyloxymethoxy.

- A suitable value for R^{10} when it is alkylamino, dialkylamino or cyclic amino is, for example, methylamino, 35 ethylamino, dimethylamino, pyrrolidino, piperidino,

4-methylpiperazino or morpholino.


A suitable value for R^{10} when it is amino-alkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, cyclic aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, dialkyl-
5 aminoalkylamino or cyclic aminoalkylamino is, for example, ethoxy, propoxy, ethylamino or propylamino substituted in the 2- or 3- position respectively by amino, methyl-
amino, ethylamino, dimethylamino, pyrrolidino, piperidino, 4-methylpiperazino or morpholino. Alternatively, R^{10}
10 when cyclic aminoalkoxy or aminoalkylamino may be a cyclic amine bearing an oxy- or amino-substituent on one of the carbon atoms of the cyclic amine, for example 1-methylpiperidin-4-yloxy or 1-methylpiperidin-4-ylamino.

When Q is carbonyl and R^6 and R^{10} are joined
15 together the group $-CR^6R^{16}-Q^3-R^{10}-$ may be, for example, the lactone group 2-oxotetrahydrofuran-3-yl or 2-oxotetrahydropyran-3-yl.

Preferably X, Y and Q are all carbonyl and R^2 and R^{11} are both hydrogen.

20 One preferred amide derivative of the invention has the formula given above wherein R^1 is alkyl of up to 15 carbon atoms which is unsubstituted or which bears an aryl, aryloxy or arylthio substituent, or R^1 is aryl or aryloxy, or R^1 is a substituent of the formula
25 $R^8CONHCHR^9-$ or $R^8COCH_2CHR^9-$ wherein R^8 is alkyl or cycloalkyl each of up to 10 carbon atoms, or aryl, and R^9 is hydrogen, or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^9 is a group other than those stated above such that the
30 compound $H_2NCH(R^9)COCH$ would be a common amino acid; wherein Y and R^2 have the meanings stated above; wherein R^3 is alkyl or alkenyl each of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^3 is aryl or indolylmethyl;

- wherein X is carbonyl, hydroxymethylene, thiocarbonyl or oximinomethylene (>C=N-OH);
 wherein R^{11} is hydrogen;
 wherein R^4 is hydrogen or alkyl of up to 5 carbon atoms
 5 which is unsubstituted or which bears an aryl substituent;
 wherein either R^5 is hydrogen, aryl or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, R^6 is hydrogen, alkyl of up to 5 carbon atoms which is unsubstituted or which bears an
 10 aryl or heterocyclic substituent, or R^6 is heterocyclic or aryl, and R^{16} is hydrogen;
 or R^5 and R^6 are joined together to form alkylene or alkenylene of 2 to 4 carbon atoms; or an oxa, thia or aza-derivative of said alkylene or alkenylene;
 15 or R^6 , R^{16} and R^5 are joined together such that R^{16} together with the first carbon atom of R^6 form a double bond wherein R^6 and R^5 are otherwise joined together as defined above;
 wherein Q is carbonyl;
 20 and wherein R^{10} has the formula $-\text{OR}^7$, wherein R^7 is hydrogen or alkyl of up to 5 carbon atoms. Thus, a preferred amide derivative has the formula:-




- wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^{16} , X and Y have the
 25 meanings stated in this paragraph.

A particularly preferred amide derivative of the invention has the formula



- wherein R^1 is methyl, benzyl, β -phenylethyl, benzyloxy, phenoxy, phenylthiomethyl, phenyl, tolyl, methoxy-phenyl, methylthiophenyl, monochlorophenyl, dichloro-phenyl, fluorophenyl, iodophenyl, nitrophenyl, cyano-phenyl, trifluoromethylphenyl, acetamidophenyl, acetyl-phenyl, methanesulphonylphenyl, biphenyl, naphthyl, benzamidomethyl, cyclopentanecarbonamidomethyl or β -benzoyl-ethyl;
- R^3 is benzyl which is unsubstituted or bears a methyl, t-butyl, methoxy, fluoro, chloro, bromo, nitro, cyano, trifluoromethyl, amino, acetamido, methanesulphonamido, trifluoromethanesulphonamido or phenyl substituent, or R^3 is 3-phenylpropyl or 3-phenylprop-2-enyl;
- R^4 is hydrogen or methyl;
- R^5 is hydrogen or methyl and R^6 is hydrogen, benzyl or indol-3-ylmethyl, or R^5 and R^6 together form trimethylene, tetramethylene, pentamethylene, 2-hydroxytrimethylene, 2-thiatrimethylene, 3-thiatetramethylene, 3-oxatetramethylene, 3-methyl-3-azatetramethylene; and
- R^{10} is hydroxy, amino, alkoxy of up to 5 carbon atoms, especially methoxy, ethoxy, isopropoxy or t-butoxy, or β -dimethylaminoethoxy or β -morpholineethoxy.

An especially preferred amide derivative of the invention has the formula




wherein R^1 is phenyl, p-acetamidophenyl or p-cyano-phenyl, R^3 is benzyl, p-methylbenzyl or p-methoxybenzyl, R^4 is hydrogen or methyl and R^{10} is hydroxy, amino, methoxy, ethoxy, isopropoxy or t-butoxy.

5 Specific compounds of the invention are hereinafter described in the Examples, and of these preferred compounds are N-(5-acetamido-2-methyl-4-oxo-6-phenylhexanoyl)-L-proline, N-(5-benzamido-2-methyl-4-oxo-6-phenylhexanoyl)-L-proline and N-(5-phenylacetamido-10 2-methyl-4-oxo-6-phenylhexanoyl)-L-proline, and salts thereof, and esters thereof with an alcohol of up to 5 carbon atoms, for example methyl and t-butyl esters thereof, and amides thereof. Of these preferred compounds are N-(5-benzamido-2-methyl-4-oxo-6-phenylhexanoyl)-L-15 proline, and its methyl ester, and its amide.


A suitable salt of an amide derivative of the invention wherein R^{10} is hydroxy is, for example, an alkali metal or alkaline earth metal salt, for example a sodium, potassium, calcium or magnesium salt, or an20 ammonium or dicyclohexylamine salt.

An amide derivative of the invention may be manufactured by any chemical process known to be suitable for preparing compounds of related chemical types.

A preferred process for the manufacture of an25 amide derivative of the invention comprises the reaction of an acid of the formula:-




wherein R^1 , R^2 , R^3 , R^4 , R^{11} , X and Y have the meanings30 stated above, or of a reactive derivative thereof, with an amine of the formula:-




wherein R^5 , R^6 , R^{16} and Q have the meanings stated above and wherein R^{12} has any of the meanings stated above for R^{10} except those containing a free hydroxy or amino group.

5 The abovementioned reaction may be carried out by reacting the acid and amine together in the presence of a carbodiimide, for example dicyclohexylcarbodiimide, and N-hydroxybenzotriazole, in a diluent or solvent, for example tetrahydrofuran, methylene chloride or dimethylformamide, at ambient temperature or below.


10 The acid starting material for the above reaction wherein R^2 is hydrogen and X and Y are both carbonyl, that is, having the formula:-



15 may be obtained by the reaction of a compound of the formula:-




wherein R^1 and R^3 have the meanings stated above, with an acid chloride of the formula:-



20 wherein R^4 and R^{11} have the meanings stated above and wherein R^{13} is alkyl of up to 5 carbon atoms, followed by the hydrolysis of the oxazolone ring and also hydrolysis to replace R^{13} by hydrogen. The starting material wherein R^2 is alkyl, arylalkyl or aryl may be
 25 obtained by the reaction of the intermediate thus obtained, wherein R^{13} is alkyl or has been replaced by hydrogen, with a compound of the formula R^2Z , wherein R^2 has the meaning stated above and wherein Z is a


displaceable group such as a halogen atom or an alkane-sulphonyl or arenesulphonyl group, for example a chlorine, bromine or iodine atom or a methanesulphonyl or toluene-p-sulphonyl group.

- 5 Alternatively, the starting material wherein R^2 is hydrogen and X is carbonyl or thiocarbonyl may be obtained by the reaction of a compound of the formula:-



- 10 wherein R^3 , R^4 , R^{11} and R^{13} have the meanings stated above and X^1 is carbonyl or thiocarbonyl, with a compound of the formula R^1-Y-Z^1 , wherein R^1 and Y have the meanings stated above and wherein Z^1 is a displaceable group such as is defined above for Z, or
 15 Z^1 is hydroxy (in which case the reaction is carried out in the presence of a carbodiimide or an alkyl chloroformate), or, when Y is amido, with a compound of the formula R^1NCO , or, when Y is thiocarbonyl, with a compound of the formula $R^1CS-SCH_2COOH$.


- 20 An alternative process for the manufacture of an amide derivative of the invention wherein R^2 is hydrogen and X is carbonyl or thiocarbonyl comprises the reaction of an amine of the formula:




- 25 wherein R^3 , R^4 , R^5 , R^6 , R^{11} , R^{12} , R^{16} , Q and X^1 have the meanings stated above, with a compound of the formula R^1-Y-Z^1 , wherein R^1 , Y and Z^1 have the meanings stated above.

- 30 Yet an alternative process for the manufacture of an amide derivative of the invention wherein R^2 is hydrogen and X is a carbonyl comprises the reaction

of a compound of the formula:-



wherein R^4 , R^5 , R^6 , R^{11} , R^{12} , R^{16} , and Q have the meanings stated above and Z^2 is a displaceable halogen atom, for example the chlorine or bromine atom, with
 5 a compound of the formula



wherein R^1 and R^3 have the meanings stated above, followed by hydrolysis of the oxazolone ring.

10 The last-mentioned reaction may be carried out in the presence of a base, for example triethylamine and/or 4-dimethylaminopyridine, and it may be carried out in a diluent or solvent, for example tetrahydrofuran.

15 An amide derivative of the invention wherein R^2 is alkyl, arylalkyl or aryl (and R^{10} is R^{12}) may be obtained by reacting the corresponding amide derivative of the invention wherein R^2 is hydrogen (and R^{10} is R^{12}) with a compound of the formula R^2Z , wherein R^2 and Z have the meanings stated above.

20 An amide derivative of the invention wherein R^3 is unsubstituted or substituted alkyl may be obtained by the hydrogenation of the corresponding compound wherein R^3 is unsubstituted or substituted alkenyl.

25 An amide derivative of the invention wherein R^{10} is other than hydroxy (that is, wherein $Q-R^{10}$ forms an ester or amide group) may be obtained from the corresponding acid wherein $Q-R^{10}$ is $-COOH$ by conventional means of ester or amide formation.

An amide derivative of the invention wherein Q is carbonyl and R¹⁰ is hydroxy may be obtained by the hydrolysis of the corresponding amide derivative of the invention wherein R¹⁰ is alkoxy, or, when R¹⁰ is t-butoxy, by the acid-catalysed cleavage of said compound.

An amide derivative of the invention wherein X is hydroxymethylene may be obtained by the reduction, for example with an alkali metal borohydride, of the corresponding amide derivative of the invention wherein X is carbonyl, and an amide derivative of the invention wherein X is oximinomethylene may be obtained by the reaction of the corresponding amide derivative of the invention wherein X is carbonyl with hydroxylamine or an O-substituted hydroxylamine derivative.

AS stated above, an amide derivative of the invention possesses ACE-inhibiting properties. ACE is the enzyme which converts angiotensin I to angiotensin II. The ACE-inhibiting properties of an amide derivative of the invention may be demonstrated by its ability to prevent the cleavage of angiotensin I or of a synthetic peptide related to angiotensin I by ACE.

Angiotensin II is a potent constrictor of vascular smooth muscle, and is therefore involved in the control of blood pressure. A compound which prevents conversion of angiotensin I to angiotensin II will therefore lower circulating levels of angiotensin II and cause a fall in blood pressure. An amide derivative of the invention may therefore be used to lower blood pressure in a warm-blooded animal (including a human). At a dose of amide derivative of the invention which lowers blood pressure in an experimental animal, for example a rat, no symptoms of toxicity are apparent.

An amide derivative of the invention may be administered to a warm-blooded animal, including man, in the form of a pharmaceutical composition comprising as active ingredient at least one amide derivative of the invention, or a salt thereof, in association with a pharmaceutically-acceptable diluent or carrier therefor.

A suitable composition is, for example, a tablet, capsule, aqueous or oily solution or suspension, emulsion, injectable aqueous or oily solution or suspension, dispersible powder, spray or aerosol formulation.

The pharmaceutical composition may contain, in addition to the amide derivative of the invention, one or more drugs selected from diuretics, for example bendrofluazide, chlorothiazide and chlorthalidone; and other hypotensive agents, for example β -adrenergic blocking agents, for example atenolol and propranolol.

When used for the treatment of hypertension in man, it is expected that the amide derivative of the invention would be given to man at a total oral dose of between 1 mg. and 500 mg. daily, at doses spaced at 6-8 hourly intervals, or at an intravenous dose of between 0.1 mg. and 50 mg.

Preferred oral dosage forms are tablets or capsules containing between 1 mg. and 100 mg. of active

ingredient. Preferred intravenous dosage forms are sterile aqueous solutions of active ingredient containing between 0.1 % and 1 % w/v of active ingredient.

The invention is illustrated but not limited
5 by the following Examples :-

Example 1


Dicyclohexylcarbodi-imide (3.0 g.) was added to a stirred, ice-cooled solution of (R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoic acid (2.77 g.), N-hydroxy-
10 benzotriazole (1.4 g.) and L-proline t-butyl ester (1.88 g.) in dry tetrahydrofuran (35 ml.), and the mixture was allowed to warm up to laboratory temperature and was then stirred at that temperature for 24 hours. Acetic acid (5 ml.) was added and 15 minutes after that
15 addition the mixture was partitioned between ethyl acetate (200 ml.) and aqueous 10% w/v sodium carbonate solution (75 ml.). The ethyl acetate layer was separated, washed successively twice with aqueous 10% w/v sodium carbonate solution, three times with aqueous N-hydrochloric
20 acid and once with saturated aqueous sodium chloride solution, filtered through anhydrous sodium sulphate and evaporated to dryness under reduced pressure. The residue was dissolved in diethyl ether, the solid dicyclohexylurea was filtered off and the ethereal
25 solution was evaporated to dryness. The residue was dissolved in methylene chloride and chromatographed on a silica gel column (344 mm. x 42 mm, Merck K60) by elution with methylene chloride and then with a 1:1 v/v mixture of methylene chloride and ethyl acetate. There
30 was thus obtained, as an oil, N-[(R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 1), the structure of which was confirmed by elemental analysis (C,H and N), by proton magnetic

resonance spectroscopy and by mass spectroscopy.

Elemental Analysis

Found: C, 64.9%; H, 8.0%; N, 5.8%. $C_{24}H_{34}N_2O_5 \cdot H_2O$
requires C, 64.4%; H, 8.05%; N, 6.2%.

Proton Magnetic Resonance Spectrum (in $CDCl_3$)



Shift (δ)	Type of Peak	No. of H Atoms	Specific H atoms
1.15	t	3	⑧
1.45	s	9	⑬
1.95	d	3	①
1.70-2.3	m	6	④, ⑩, ⑪
3.0	m	3	⑥, ⑦
3.60	m	2	⑨
4.31	m	1	③
4.70	m	1	⑫
6.25/6.55/6.68	m	1	②
7.20	s	5	⑤

Mass Spectrum (70 ev)

	<u>Mass No.</u>	<u>Ion</u>
	431	$M^+ + 1$
	430	$C_{24}H_{34}N_2O_5(M^+)$
5	374	$M - C_4H_8$
	357	$M - C_4H_9O$
	329	$M - COOC(CH_3)_3$
	268	$M - CH_3CONHCH(CH_2C_6H_5)$
	260	$M - \text{Proline t-butyl ester}$
10	260	$M - CH_3CONH$

The (R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoic acid used as starting material was prepared as follows:-

A solution of 3-methoxycarbonylbutyric acid
 15 (29.2 g.; J.Org.Chem., 1972, 37, 555) and oxalyl chloride (31.5 g.) in benzene (100 ml.) was stirred at laboratory temperature for 4 hours, evaporated to dryness under reduced pressure and then twice re-evaporated to dryness from an excess of methylene chloride. A solution of the
 20 3-methoxycarbonylbutyryl chloride thus obtained (20 g.) in dry tetrahydrofuran (40 ml.) was added dropwise during 15 minutes to a stirred solution of freshly distilled 4-benzyl-2-methyl-5(4H)-one (17.7g.;
 prepared from phenylalanine and acetic anhydride as
 25 described in Annalen, 1926, 449, 277), 4-dimethylamino-pyridine (0.7 g.) and triethylamine (27 ml.) in dry tetrahydrofuran (100 ml.) which had been cooled to $-50^\circ\text{C}.$, at such a rate that the temperature of the mixture did not exceed $-30^\circ\text{C}.$ The stirred mixture was allowed to


warm up to laboratory temperature during 4 hours and
was then stirred at laboratory temperature for 70 hours.
Acetic acid (30 ml.) was added and the mixture was
allowed to stand at laboratory temperature for 1 hour
5 and then evaporated to dryness. The residue was
partitioned between ethyl acetate (500 ml.) and aqueous
2N-hydrochloric acid (200 ml.), and the ethyl acetate
layer was washed successively twice with aqueous 2N-
hydrochloric acid, three times with 10% w/v aqueous
10 sodium carbonate solution and once with saturated aqueous
sodium chloride solution, filtered through anhydrous
sodium sulphate and evaporated to dryness under reduced
pressure. The residue was purified by chromatography
on a 30 cm. x 5 cm. silica gel column using a 1:1 v/v
15 mixture of ethyl acetate and methylene chloride as
eluant, and there was thus obtained methyl (R,S)-5-
acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoate
(24.75 g.).

A mixture of the above ester (12.6 g.) and
20 aqueous 2N-sodium hydroxide solution (100 ml.) was kept
at laboratory temperature for 4 hours, washed twice
with diethyl ether and then acidified with aqueous 2N-
hydrochloric acid and extracted with ethyl acetate.
The extract was washed with saturated aqueous sodium
25 chloride solution, filtered through anhydrous sodium
sulphate and evaporated to dryness under reduced
pressure. The residue was crystallised from a mixture
of ethyl acetate and ether and there was thus obtained
(R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoic
30 acid, m.p. 115-127°C.

Example 2

The process described in Example 1 was repeated
except that the appropriate 4-oxo-6-phenylhexanoic acid
and the appropriate L-proline ester were used as starting

materials. There were thus obtained the compounds described in the following table:-



	R^1	R^4	R^7	Compound No
5	methyl	methyl	methyl	2
	methyl	H	methyl	3
	methyl	benzyl	methyl (more polar isomer)	4
	methyl	benzyl	methyl (less polar isomer)	5
	phenyl	methyl	t-butyl	6
10	phenyl	H	t-butyl	7
	benzyl	methyl	t-butyl (more polar isomer)	8
	benzyl	methyl	t-butyl (less polar isomer)	9
	benzyl	H	t-butyl	10
	benzamidomethyl	H	t-butyl	11
	cyclopentanecarbon-amidomethyl	methyl	t-butyl	12
	cyclopentanecarbon-amidomethyl	H	t-butyl	13
	n-tridecyl	methyl	t-butyl	14

The isomeric Compounds Nos 4 and 5, and Compounds Nos. 8 and 9, were separated from each other by the final chromatography step. The structures of all the compounds were confirmed by elemental analysis, proton magnetic resonance spectroscopy and also (in the case of Compounds Nos 2,3,4,5,6,10,11 and 13) by mass spectroscopy.

Example 3

The process described in Example 1 was repeated except that L-phenylalanine ethyl ester was used in place of L-proline t-butyl ester. There was thus obtained, as an oil, N-[(R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-phenylalanine ethyl ester (Compound No. 15), the structure of which was confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy.

Example 4

The process described in Example 1 was repeated except that (R,S)-5-acetamido-4-oxo-6-phenylhexanoic acid and N-benzylglycine ethyl ester were used as starting materials. There was thus obtained N-[(R,S)-5-acetamido-4-oxo-6-phenylhexanoyl]-N-benzylglycine ethyl ester (Compound No. 16), the structure of which was confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy.

The starting materials (hexanoic acids) used to prepare Compounds Nos. 2 to 14 and 16 described in Examples 2 and 4 were prepared by similar methods to those used to prepare the hexanoic acid described in the second part of Example 1. Particular intermediates used were as follows:-

(a) 3-ethoxycarbonyl-4-phenylbutyric acid (for Compounds Nos. 4 and 5); monomethyl succinate (for Compounds Nos. 3, 7, 10, 11, 13 and 16).

(b) 2,4-dibenzyl-oxazol-5(4H)-one (for

Compounds Nos. 8, 9 and 10); 4-benzyl-2-

phenyloxazol-(4H)-one (for Compounds Nos. 6 and 7)
(the preparation of the two last-mentioned compounds
is described below).

(c) methyl (R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-
5 6-phenylhexanoate (for Compound No 6); ethyl (R,S)-5-
phenylacetamido- (R,S)-2-methyl-4-oxo-6-phenylhexanoate
(for Compounds Nos 8 and 9); ethyl (R,S)-5-acetamido-
(R,S)-2-benzyl-4-oxo-6-phenylhexanoate (for Compounds
Nos 4 and 5); methyl (R,S)-5-benzamido-4-oxo-6-phenyl-
10 hexanoate (for Compound No. 7); methyl (R,S)-5-acetamido-
4-oxo-6-phenylhexanoate (for Compounds Nos 3 and 16).


The 2,4-dibenzyl-oxazol-5(4H)-one used
as an intermediate in the preparation of Compounds Nos.
8 and 9 was prepared by the reaction of (N-phenylacetyl)-
15 phenylalanine with dicyclohexylcarbodi-imide, and the
4-benzyl-2-phenyloxazol-5(4H)-one was similarly
prepared from (N-benzoyl)phenylalanine.

The hexanoic acid starting materials used for
the preparation of Compounds Nos. 10 to 14 (and also
20 alternatively for Compounds Nos. 8 and 9) were prepared
from the appropriate methyl (R,S)-5-acetamido-4-oxo-6-
phenylhexanoate, by replacing the 5-acetamido group
by the appropriate amido group, as exemplified by the
following procedure:

25 A mixture of ~~methyl (R,S)-5-acetamido-~~
~~(R,S)-2-methyl-4-oxo-6-phenylhexanoate~~ (10.11 g.) and
aqueous 6N-hydrochloric acid (100 ml.) was heated
at 100°C. for 6 hours, kept at laboratory temperature
for 17 hours and then evaporated to dryness under
30 reduced pressure. Thionyl chloride (5 ml.) was added.
during 15 minutes to a stirred, ice-cooled solution of
the residue in methanol (100 ml.) and the mixture was
stirred at laboratory temperature for 3 hours and then
evaporated to dryness under reduced pressure. A mixture
35 of the methyl (R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenyl-

hexanoate hydrochloride thus obtained (5.7 g.),
(N-cyclopentanecarbonyl)glycine (2.87 g.) and tetra-
hydrofuran (50 ml.) was stirred and ice-cooled,
and N-hydroxybenzotriazole (2.6 g.), triethylamine (10 ml.)
5 and dicyclohexylcarbodi-imide (4.12 g.) were sequentially
added. The mixture was kept at laboratory temperature
for 17 hours and filtered, and the filtrate was evap-
orated to dryness under reduced pressure. The residue
was partitioned between ethyl acetate and aqueous
10 2N-hydrochloric acid, and the ethyl acetate layer was
separated, washed successively twice with aqueous 2N-
hydrochloric acid, three times with aqueous 10% w/v
sodium carbonate solution and once with saturated
aqueous sodium chloride solution, filtered through
15 anhydrous sodium sulphate and evaporated to dryness.
The residue was stirred with diethyl ether, the solid
dicyclohexylurea was filtered off and the ethereal
solution was evaporated to dryness. The residue was
dissolved in methylene chloride and chromatographed on
20 a silica gel column using a 1:1 v/v mixture of methylene
chloride and ethyl acetate as eluant. There was thus
obtained, as an oil, methyl (R,S)-5-(N-cyclopentane-
carbonyl)glycinamido-(R,S)-2-methyl-4-oxo-6-phenyl-
hexanoate.


25 This ester was then hydrolysed to the hexanoic
acid by a similar procedure to that described in the last
paragraph of Example 1. There was thus obtained (R,S)-
5-(N-cyclopentanecarbonyl)glycinamido-(R,S)-2-methyl-
4-oxo-6-phenylhexanoic acid, the structure of which was
30 confirmed by proton magnetic resonance spectroscopy and
mass spectroscopy. This compound was used to prepare
Compound No. 12. There were similarly obtained the
compounds shown in the following table, all of which
structures were similarly confirmed:-



R^1	R^4	Intermediate for Compound No.
cyclopentanecarbon amidomethyl	H	13
benzamidomethyl-	H	11
benzyl	methyl	8,9
benzyl	H	10
tridecyl	methyl	14

Example 5

A mixture of N-[(R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Example 1, Compound No. 1, 3.04 g.) and a 9:1 v/v mixture of trifluoroacetic acid and water (20 ml.) was stirred at laboratory temperature for 2 hours, evaporated to dryness under reduced pressure and then re-evaporated to dryness from toluene and then from cyclohexane. The residue was dissolved in methylene chloride and chromatographed on silica gel using a 3% v/v solution of methanol in methylene chloride as eluant. There was thus obtained N-[(R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 21), the structure of which was confirmed by proton magnetic resonance spectroscopy and by mass spectroscopy.

Proton Magnetic Resonance Spectrum (in CDCl₃)

Shift (δ)	Type of Peak	No. of H Atoms	Specific H atoms
1.08	t	3	⑧
1.91	m	3	①
2.10	m	5	⑦, ⑩, ⑪
3.00	m	4	④, ⑥
3.62	m	2	⑨
4.45	m	1	③
4.71	t	1	⑫
6.50	t	1	②
7.20	s	5	⑤
8.24	s	1	⑬


Mass Spectrum (70 ev)

	<u>Mass No.</u>	<u>Ion</u>
	374	$C_{20}H_{26}N_2O_5 (M^+)$
	356	$M - H_2O$
5	330	$M - CO_2$
	283	$M - CH_2C_6H_5$
	260	$M - \text{Proline}$
	212	$M - CH_3CONHCH(CH_2C_6H_5)$
	168	$(212 - CO_2)$
10	162	$CH_3CONH^{\oplus} = CHCH_2C_6H_5$

A sample of Compound 21 was dissolved in ethyl acetate and a solution of dicyclohexylamine in a mixture of ethyl acetate and ether was added. The mixture was filtered and the solid residue was crystallised from ethyl acetate. There was thus obtained the hemi-hydrate of the dicyclohexylamine salt of Compound 21, m.p. 191-194°C., the structure of which was confirmed by elemental analysis (Found: C, 68.5%; H, 9.1%; N, 7.2%. $C_{32}H_{49}N_3O_5 \cdot \frac{1}{2}H_2O$ requires: C, 68.1%; H, 8.9%; N, 7.4%).

Example 6

The process described in Example 5 was repeated using the appropriate ester as starting material. There were thus obtained the compounds described in the following table:



Starting Material Compound No.	R ¹	R ⁴	Acid Compound No.
6	phenyl	methyl	26
7	phenyl	H	27
8	benzyl	methyl	28
9	benzyl	methyl	29
10	benzyl	H	30
11	benzamidomethyl	H	31
12	cyclopentanecarbon- amidomethyl	methyl	32
13	cyclopentanecarbon- amidomethyl	H	33


The structures of all these compounds were confirmed by proton magnetic resonance spectroscopy.

Example 7

A solution of potassium hydroxide (0.7 g.) in water (10 ml.) was added to a solution of N-[(R,S)-5-acetamido-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (Example 2, Compound No. 3, 2.15 g.) in ethanol (40 ml.) and the mixture was stirred at laboratory temperature for 1 hour, acidified to pH 4 with aqueous 2N-hydrochloric acid, diluted with saturated aqueous sodium chloride solution and extracted three times with chloroform (15 ml. each time). The combined extracts were washed with saturated aqueous sodium chloride solution and then evaporated to dryness. There was thus obtained N-[(R,S)-5-acetamido-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 23), m.p. 50-60°C.,

the structure of which was confirmed by elemental analysis and proton magnetic resonance spectroscopy.

The process described above was repeated using the appropriate methyl or ethyl ester as starting material and there were thus obtained the compounds shown in the following table:




Starting Material Compound No.	R ¹	R ⁴	R ⁵	R ⁶	Acid Compound No.
4	methyl	benzyl	-(CH ₂) ₃ -		24
5	methyl	benzyl	-(CH ₂) ₃ -		25
15	methyl	methyl	H	benzyl	35
16	methyl	H	benzyl	H	36

The structures of all these compounds were confirmed by proton magnetic resonance spectroscopy.

Example 8

The process described in Example 1 was repeated except that the appropriate (R,S)-5-acylamino-4-oxo-6-phenyl-hexanoic acid (prepared by a similar process to that described in Example 4 for the preparation of intermediates for Compounds Nos. 10 to 14) and L-proline t-butyl ester were used as starting materials. There were thus obtained, as oils, the compounds described in the following table, the structures of which were all confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy:-



R ¹	Compound No.
4-acetamidophenyl	17
4-methoxyphenyl	18
2-naphthyl	19
β-phenylethyl	20
β-benzoylethyl	41
γ-phenoxypropyl	42
benzyloxy	43
4-nitrophenyl	278
4-chlorophenyl	279

Example 9

N,N'-Dicyclohexylcarbodi-imide (38.3 g.) was added
 5 to a stirred solution of (R,S)-5-benzyloxycarbonylamino-
 4-oxo-6-phenylhexanoic acid (60 g.), L-proline t-butyl
 ester (30.5 g.) and N-hydroxybenzotriazole (24 g.) in
 dry tetrahydrofuran (750 ml.) which was cooled to 0°C.,
 and the mixture was allowed to warm up to laboratory
 10 temperature and was then stirred for 18 hours. The
 mixture was cooled to 0°C and filtered, and the filtrate
 was evaporated to dryness under reduced pressure.
 The residue was dissolved in ethyl acetate and the
 solution was washed successively with aqueous 3% w/v
 15 citric acid solution, aqueous 5% w/v sodium bicarbonate
 solution and saturated aqueous sodium chloride solution,
 dried over sodium sulphate and evaporated to dryness under
 reduced pressure. The residual oil was purified by
 chromatography on a silica gel column using a 1:1 v/v
 20 mixture of ethyl acetate and methylene chloride as eluant,

and there was thus obtained as an oil N-[(R,S)-5-benzyloxy-carbonylamino-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 43).

A solution of the above oil, which consists of
5 two isomers (59 g.), in diethyl ether (300 ml.) was kept at laboratory temperature for 18 hours and then filtered. The solid product was crystallised from a mixture of ethyl acetate and petroleum ether (b.p. 40-60°C.) and there was thus obtained one isomer
10 (hereinafter Isomer A) of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline t-butyl ester, m.p. 126-128°C. (Compound No. 43A)

The diethyl ether mother liquors from the initial crystallisation were evaporated to dryness
15 under reduced pressure. There was thus obtained as an oil a second isomer (hereinafter Isomer B) of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline t-butyl ester (Compound No. 43B).

The structures of both isomers A and B were
20 confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy.

The (R,S)-5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoic acid used as starting material was obtained as follows:-

25 A mixture of methyl (R,S)-5-acetamido-4-oxo-6-phenylhexanoate (9.5 g; the same intermediate as is described in Example 4 as an intermediate for Compounds Nos. 3 and 16) and aqueous 6N-hydrochloric acid (100 ml.) was heated at 100°C. for 6 hours, cooled and evaporated
30 to dryness under reduced pressure. Toluene (100 ml.) was added and the mixture again evaporated to dryness under reduced pressure. There was thus obtained as oily residue (R,S)-5-amino-4-oxo-6-phenylhexanoic acid hydrochloride. A suspension of sodium bicarbonate (10 g.)
35 in water (50 ml.) was cautiously added to a stirred

solution of the above hydrochloride (9.25 g.) in water (100 ml.), and after evolution of carbon dioxide had ceased a solution of benzyl chloroformate (6.1 ml.) in acetone (20 ml.) was added and the mixture was stirred
5 at 5°C. for 18 hours. The mixture was washed with diethyl ether (200 ml.) and then acidified to pH 2 with concentrated aqueous hydrochloric acid, and filtered. The solid residue was washed with water (200 ml.) and there was thus obtained (R,S)-5-benzyloxycarbonylamino-
10 4-oxo-6-phenylhexanoic acid, 107-109.

Example 10

Potassium t-butoxide (0.2 g.) was added to a solution of Isomer B of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline t-butyl ester (25 g.)
15 in diethyl ether (200 ml.) and the mixture was kept at laboratory temperature for 5 days and then filtered. The solid residue was crystallised from a mixture of ethyl acetate and petroleum ether (b.p. 40-60°C, and there was thus obtained Isomer A of N-(5-benzyloxy-
20 carbonylamino-4-oxo-6-phenylhexanoyl)-L-proline t-butyl ester, m.p. 126-128°C.

Example 11

A mixture of Isomer A of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline-t-butyl ester
25 (1.0 g.), trifluoroacetic acid (18 ml.) and water (2 ml.) was kept at laboratory temperature for 40 minutes and then evaporated to dryness under reduced pressure. Toluene (30 ml.) was added and the mixture was again evaporated to dryness under reduced pressure, finally
30 at 0.1 mm.Hg. There was thus obtained as oily residue Isomer A of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline (Compound No. 143A), the structure of which was confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy.

The process described above was repeated using the t-butyl ester Isomer B in place of Isomer A, and there was thus obtained Isomer B of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline (Compound No. 143B).

5 Example 12


A 30% palladium-on-charcoal catalyst (0.1 g.) was suspended in a solution of Isomer A of N-(5-benzyloxycarbonylamino-4-oxo-6-phenylhexanoyl)-L-proline (0.9 g.) in a mixture of ethanol (30 ml.) and aqueous N-hydrochloric
10 acid (2.0 ml.), and hydrogen was bubbled through the mixture for 75 minutes. The mixture was filtered and the filtrate was evaporated to dryness under reduced pressure. Toluene (30 ml.) was added and the mixture was again evaporated to dryness under reduced pressure,
15 finally at 0.1 mm/Hg. There was thus obtained, as a foam, Isomer A of N-(5-amino-4-oxo-6-phenylhexanoyl)-L-proline hydrochloride (Compound No. 144A), the structure of which was confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy.

20 The process described above was repeated using the corresponding Isomer B as starting material in place of Isomer A, and there was thus obtained Isomer B of N-(5-amino-4-oxo-6-phenylhexanoyl)-L-proline hydrochloride (Compound No 144B), also as a foam.

25. Example 13

Sodium bicarbonate (0.8 g.) was added to a stirred solution of Isomer A of N-(5-amino-4-oxo-6-phenylhexanoyl)-L-proline hydrochloride (0.71 g.) in water (30 ml.), and after evolution of carbon dioxide
30 had ceased a solution of p-cyanobenzoyl chloride (0.4g) in acetone (5 ml.) was added and the mixture was stirred at laboratory temperature for 4 hours and then washed with diethyl ether (30 ml.). The aqueous solution was acidified to pH 3 with aqueous 2N-hydrochloric acid,
35 and then extracted with ethyl acetate (60 ml.).

The process described above was repeated using the appropriate acid chloride and either Isomer A or Isomer B of N-(5-amino-4-oxo-6-phenylhexanoyl)-L-proline hydrochloride as starting materials, and where necessary purifying the product obtained by chromatography on a silica gel column using a 2.5% v/v solution of acetic acid in ethyl acetate as eluant. There were thus obtained the compounds described in the following table, all of which were non-crystalline and the structures of which were confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy:-




R ¹	Isomer	Compound No.
phenyl	A	27A
phenyl	B	27B
3,4-dichlorophenyl	A	147A
4-amino-3,5-dichlorophenyl	A	148A
2-trifluoromethylphenyl	A	149A
3,4,5-trimethoxyphenyl	A	150A
4-methylthiophenyl	B	151B
3,5-dinitrophenyl	B	152B
2-carboxyphenyl	B	153B
4-biphenyl	B	154B
cyclohexyl	A	155A
cyclopropyl	B	156B

/continued.....

R^1	Isomer	Compound No
phenyl-CH=CH-	B	157B
phenyl-CH=CCl-	A	158A
phenyl-CH=CCl-	B	158B
(phenyl) ₂ CH-	B	159B
$\begin{array}{c} \text{CF}_3 \\ \\ \text{phenyl-C-} \\ \\ \text{OCH}_3 \end{array}$	$\left\{ \begin{array}{l} \text{A} \\ \text{B} \end{array} \right.$	$\left. \begin{array}{l} 160A \\ 160B \end{array} \right\} \text{Note 1}$

Note 1. These two compounds were prepared from (+)-2-methoxy-2-phenyl-3,3,3-trifluoropropionic acid (Dale et al., J.Organic Chemistry, 1969, 34, 2543), were purified by chromatography on a silica gel column using a 2% v/v solution of acetic acid in ethyl acetate as eluant, and served to distinguish Isomers A and B.


The elemental analysis, ¹³C and ¹⁹F nuclear magnetic resonance spectra and mass spectra of the two isomers were identical, but Isomer A had a larger retention time than Isomer B on high pressure liquid chromatography, and the proton magnetic resonance spectra were different as shown below:



δ -values (p.p.m.) (No. of H atoms and type of peak)		Specific H Atoms
Isomer A	Isomer B	
7.40 (5H, singlet)	7.35-7.20 (5H, multiplet)	} ① + ②
7.20 (5H, singlet)	7.15 (5H, singlet)	
3.19 (3H, multiplet)	3.28 (3H, multiplet)	③
2.63 (2H, multiplet)	2.74 (2H, multiplet)	④

The proton magnetic resonance spectra showed that Isomer A was uncontaminated by Isomer B, but that Isomer B was sometimes contaminated by a small amount
5 of Isomer A.

The process described above was repeated using the appropriate acid chloride (or phenyl isocyanate*), and Isomer A of N-(5-amino-4-oxo-6-phenylhexanoyl)-L-proline t-butyl ester (prepared from Compound 43A of
10 Example 9 by hydrogenolysis of the benzyloxycarbonyl group by a similar process to that described in Example 12) as starting materials. There were thus obtained the compounds described in the following table, all of which
15 were non-crystalline and the structures of which were confirmed by elemental analysis, proton magnetic resonance spectroscopy and mass spectroscopy:



R^1	Compound No.
phenyl-CH ₂ -CH (NHCOOCH ₂ C ₆ H ₅)-	61A
CH ₃ CH(NHCOOCH ₂ C ₆ H ₅)-	62A
phenyl-NH- *	63A

Example 14

The process described in the first part of Example 9 was repeated except that (R,S)-5-benzyloxycarbonylamino-(R,S)-2-methyl-4-oxo-6-phenylhexanoic acid was used as
 10 starting material in place of the 2-unsubstituted compound. There was thus obtained N-[(R,S)-5-benzyloxycarbonylamino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester monohydrate (Compound No. 65), the structure of which was confirmed by elemental analysis and infra-red
 15 spectroscopy.

The hexanoic acid used as starting material was obtained as an oil from methyl (R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoate (Example 1) and benzyl chloroformate by a similar procedure to that described
 20 in the last part of Example 9.

Example 15

The process described in Example 5 was repeated except that N-[(R,S)-5-benzyloxycarbonylamino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No 65, Example 14) was used as starting material, and that the product was purified by chromatography on silica gel using a 9:9:1:1 v/v/v/v mixture of ethyl acetate: toluene: formic acid: methanol as eluant. There was thus obtained N-[(R,S)-5-benzyloxycarbonylamino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No 165) as an oil, the structure of which was confirmed by elemental analysis and infrared spectroscopy.


Example 16

The process described in Example 12 was repeated except that N-[(R,S)-5-benzyloxycarbonylamino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 165, Example 15) was used as starting material. There was thus obtained N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline hydrochloride sesquihydrate (Compound No. 166) as a pale yellow solid, the structure of which was confirmed by elemental analysis.

Example 17

Thionyl chloride (15ml.) was added to a stirred solution of N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline hydrochloride (5g.) in methanol (50 ml.) which was maintained at -20°C., and the mixture was then stirred for 24 hours, evaporated to dryness and toluene was added and reevaporated until all thionyl chloride had been removed. There was thus obtained as oily residue N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (Compound No. 67), the structure of which was confirmed by elemental analysis.

The process described in Example 13 was repeated except that N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline hydrochloride (Example 16) or the methyl ester thereof (Example 17) and the appropriate acyl chloride were used as starting materials. There were thus obtained, as oils, the compounds described in the following table, the structures of which were all confirmed by elemental analysis and spectroscopic procedures:-



R ¹	R ⁷	Compound No.
2-tolyl	H	168
3-tolyl	H	169
4-tolyl	H	170
3,5-dimethylphenyl	H	171
2-methoxyphenyl	H	172
2-methoxyphenyl	methyl	72
3-methoxyphenyl	H	173
3-methoxyphenyl	methyl	73
4-fluorophenyl	H	174
2,6-difluorophenyl	H	175
3-iodophenyl	H	176
3-iodophenyl	methyl	76 (Note 1)
4-acetylphenyl	H	177
4-methanesulphonylphenyl	H	178
phenoxymethyl	H	179
phenylthiomethyl	H	180

Continued....

Continuation....

R ¹	R ⁷	Compound No.
β -phenylethyl	H	181
phenoxy	H	182
p-hydroxyphenyl	H	183 (Note 2)

Note 1 The methyl ester was prepared by the reaction of the corresponding acid with thionyl chloride and methanol by a similar procedure to that described in Example 17.

Note 2 p-Acetoxybenzoyl chloride was used as starting material, the acetyl group being removed by shaking the final ethyl acetate solution with dilute aqueous sodium hydroxide solution and then acidifying the aqueous layer and extracting with ethyl acetate.


Example 19

N-Methylmorpholine (1.1 g.) and isobutyl chloroformate (0.67 g.) were added to a stirred solution of o-ethoxycarbonylmethylbenzoic acid (1 g.) in tetrahydrofuran (40 ml.) which was cooled to -20°C., and the mixture was stirred at that temperature for 30 minutes. A solution of N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (0.9 g.) in tetrahydrofuran (6 ml.) was added and the mixture was stirred for 5 hours and then evaporated to dryness. The residue was dissolved in ethyl acetate and the solution was washed successively with aqueous 2N-hydrochloric acid, saturated aqueous sodium bicarbonate solution and water, dried over magnesium sulphate and evaporated to dryness under reduced pressure. The residue was purified by chromatography on a silica gel column using a 49.5 : 49.5 : 1 v/v/v mixture of ethyl acetate, petroleum ether (b.p. 60-80°C) and formic

acid as eluant. There was thus obtained N-[(R,S)-5-
o-ethoxycarbonylmethylbenzamido-(R,S)-2-methyl-4-oxo-
 6-phenylhexanoyl]-L-proline methyl ester (Compound No.
 84), the structure of which was confirmed by elemental
 5 analysis and spectroscopic procedures.

The process described above was repeated
 using the appropriate acid in place of o-ethoxy-
 carbonylmethylbenzoic acid, and there were thus obtained
 the compounds described in the following table:-

10



R^1	Compound No.
<u>p</u> -acetamidophenyl	85
2-(benzyloxycarbonylamino)ethyl*	86
2-aminoethyl*	87
ethoxy	88

* Derived from L-alanine.

The process described above was repeated except that p-acetamidobenzoic acid and N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline isopropyl ester (prepared by a similar process to that described in Example 17 except that isopropanol was used in place of methanol) were used as starting materials. There was thus obtained N-[(R,S)-5-p-acetamidobenzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline isopropyl ester (Compound No. 280).

10

The process described above was repeated except that p-acetamidobenzoic acid and N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 166; Example 16) were used as starting materials.

15

There was thus obtained N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline. (Compound No. 185).

Example 20

A solution of N,N-dicyclohexylcarbodi-imide in methylene chloride (2 ml.) was added to a stirred solution of (R,S)-5-benzamido-6-p-cyanophenyl-(R,S)-2-methyl-4-oxohexanoic acid (0.75 g.) and 1-hydroxy-benzotriazole (0.3 g.) in methylene chloride (7.5 ml.) which was cooled to 0°C. under an atmosphere of argon, and the mixture was stirred at laboratory temperature for 1 hour and then recooled to 0°C. A solution of L-proline isopropyl ester (0.35 g.) in methylene chloride (2 ml.) was added and the mixture was stirred at laboratory temperature for 16 hours and filtered, and the filtrate was evaporated to dryness under reduced pressure. The residue was purified by chromatography on a silica gel column using a 1:1 v/v mixture of ethyl acetate and toluene as eluant, and there was thus obtained as an oil N-[(R,S)-5-benzamido-6-p-cyanophenyl-(R,S)-2-methyl-4-oxohexanoyl]-L-proline isopropyl ester (Compound No. 89), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The (R,S)-5-benzamido-6-p-cyanophenyl-(R,S)-2-methyl-4-oxohexanoic acid used as starting material was obtained as follows:-

A solution of 3-methoxycarbonylbutyryl chloride (prepared as described in Example 1 from 32.1 g. of 3-methoxycarbonylbutyric acid) in tetrahydrofuran (50 ml.) was added during 5 minutes to a stirred solution of 2-phenyloxazol-5 (4H)-one (32 g.) and 4-dimethylamino-pyridine (0.5 g.) in tetrahydrofuran (1000 ml.) which was cooled to -30°C. under an atmosphere of argon, and the mixture was stirred at -30°C. for 30 minutes and then poured into vigorously stirred ice-water (200 ml.). The mixture was acidified to pH 3 with aqueous N-hydrochloric acid and filtered, and the solid product

was washed with water, dried over phosphorus pentoxide and crystallised from acetone. There was thus obtained 4-(3-methoxycarbonylbutyryl)-2-phenyloxazol-5(4H)-one, m.p. 151-154°C.

5 Triethylamine (1 ml.) and p-cyanobenzyl bromide (1.35 g.) were added to a stirred solution of the above oxazolone (2 g.) in dimethylformamide (10 ml.) and the mixture was stirred at laboratory temperature for 16 hours and then poured into aqueous 5% hydro-
10 chloric acid (100 ml.). The mixture was extracted 5 times with diethyl ether (25 ml. each time) and the combined extracts were washed twice with saturated aqueous sodium bicarbonate solution (25 ml. each time) and twice with saturated aqueous sodium chloride solution
15 (25 ml. each time), dried over magnesium sulphate and evaporated to dryness. The residue was dissolved in acetic acid (15 ml.) containing 4-dimethylamino-piperidine (0.05 g.) and the mixture was heated under reflux for 4 hours and then evaporated to dryness
20 under reduced pressure. The residue was purified by chromatography on a silica gel column using a 4:1 v/v mixture of toluene and ethyl acetate as eluant. There was thus obtained methyl (R,S)-5-benzamido-6-p-cyanophenyl-(R,S)-2-methyl-4-oxohexanoate as an
25 oil.


A mixture of the above ester (1.85 g.), methanol (10 ml.) and aqueous 2N-sodium hydroxide solution (8 ml.) was stirred at laboratory temperature for 2 hours, acidified with aqueous 2N-hydrochloric acid and extracted
30 3 times with ethyl acetate (25 ml. each time). The combined extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated to dryness. There was thus obtained as residue (R,S)-5-benzamido-6-p-cyanophenyl-(R,S)-2-
35 methyl-4-oxohexanoic acid.

The L-proline isopropyl ester used as starting material was obtained as follows:-

Thionyl chloride (30 ml.) was added to isopropanol (130 ml.) which was cooled to -50°C ., the mixture was
5 allowed to warm up to -10°C and L-proline (23 g.) was added. The mixture was stirred at laboratory temperature for 16 hours, heated under reflux for 30 minutes and the excess of isopropanol and thionyl chloride were removed by evaporation under reduced pressure
10 followed by azeotropic distillation of toluene. The hydrochloride salt thus obtained (1.3 g.) was added to aqueous 75% w/v sodium carbonate solution (10 ml.) at 0°C . and the mixture was extracted 3 times with diethyl ether. The combined extracts were dried over
15 magnesium sulphate and evaporated to dryness and there was thus obtained as residue L-proline isopropyl ester.

Example 21

The process described in Example 20 was repeated using the appropriate (R,S)-5-benzamido- 6-substituted-
20 phenyl-(R,S)-2-methyl-4-oxohexanoic acid (prepared by similar means to those described in Example 20) and the appropriate L-proline ester as starting materials, and there were thus obtained the compounds described in the following table, all of which were oils, the
25 structures of which were confirmed by elemental analysis and spectroscopic procedures




R ³	R ⁷	Compound No
4-methylbenzyl	isopropyl	94
4-methoxybenzyl	isopropyl	90
4-cyanobenzyl	t-butyl	91
4-methylbenzyl	t-butyl	92
4-methoxybenzyl	t-butyl	93
2-chlorobenzyl	isopropyl	275
2-chlorobenzyl	t-butyl	276
3-chlorobenzyl	isopropyl	277


The process described in Example 20 was repeated except that (R,S)-5-benzamido-6-p-cyanophenyl-4-oxohexanoic acid and L-proline t-butyl ester were used as starting materials. There was thus obtained, as an oil, N-[(R,S)-5-benzamido-6-p-cyanophenyl-4-oxohexanoyl]-L-proline t-butyl ester (Compound No. 95). the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The (R,S)-5-benzamido-6-p-cyanophenyl-4-oxo-hexanoic acid (m.p. 182-184°C.) used as starting material was obtained by a similar process to that described in the second part of Example 20 except that 3-methoxy-
15 carbonylpropionyl chloride was used as initial starting material.

The process described in Example 20 was repeated using the appropriate (R,S)-5-benzamido-6-
20 substituted-phenyl-4-oxohexanoic acid (prepared by a similar process to that described in the second part

of Example 22) and the appropriate L-proline ester, as starting materials, and there were thus obtained the compounds described in the following table:-



R ³	R ⁷	Compound No
p-methylbenzyl	t-butyl	207
p-methylbenzyl	methyl	96
m-methylbenzyl	t-butyl	97
m-methylbenzyl	methyl	98
o-methylbenzyl	t-butyl	99
p-chlorobenzyl	t-butyl	100
p-fluorobenzyl	t-butyl	201
p-fluorobenzyl	methyl	202
o-bromobenzyl	t-butyl	203
3,4-dichlorobenzyl	t-butyl	204
p-methoxybenzyl	t-butyl	205
p-nitrobenzyl	t-butyl	206
benzyl	benzyl	281
m-cyanobenzyl	t-butyl	208
p-trifluoromethylbenzyl	t-butyl	209
2-phenylethyl	t-butyl	210 Note 1
3-phenylpropyl	t-butyl	211 Note 2
3-phenylprop-2-enyl	t-butyl	212
naphth-1-ylmethyl	t-butyl	213
naphth-2-ylmethyl	t-butyl	214
	t-butyl	215 Note 3

Note 1 The starting material was prepared from 3-methoxycarbonylpropionyl chloride and 4-(2-phenylethyl)-2-phenyloxazol-5(4H)-one by a similar method to that described in the second part of Example 1, but including
5 the step of heating with 4-dimethylaminopyridine in acetic acid as described in the third part of Example 20. The 4-(β -phenylethyl)-2-phenyloxazol-5(4H)-one (m.p. 119-122°C.) was itself obtained by the reaction of β -phenylethyl bromide with diethyl acetamidomalonate in the
10 presence of sodium ethoxide, then hydrolysis of the acetamido group with concentrated aqueous hydrochloric acid to give 2-amino-4-phenylbutyric acid hydrochloride; acylation of the amino group with benzoyl chloride in aqueous acetone to give 2-benzamido-4-phenylbutyric
15 acid (m.p. 139-141°C.) and finally treatment of this acid with N-(3-dimethylaminopropyl)-N'-ethylcarbodi-imide hydrochloride in methylene chloride solution at 5°C.

Note 2 The starting material was prepared as described under Note 1 from 4-(3-phenylpropyl)-2-phenyloxazol-5(4H)-one, which itself was obtained by hydrogenation
20 of 4-(3-phenyl prop-1-ylidene)-2-phenyloxazol-5(4H)-one (prepared by a similar process to that described in Chemistry and Industry, 1954, 191) with a 10% palladium-on charcoal catalyst in dioxane solution. The intermediate
25 methyl (R,S)-5-benzamido-4-oxo-8-phenyloctanoate had m.p. 110-112°C.

Note 3 The starting material was (R,S)-5-benzamido-6-p-carboxyphenyl-4-oxohexanoic acid, and a second
30 molecule of L-proline t-butyl ester formed an amide with the p-carboxy group.

The process described above was repeated except that (R,S)-5-benzamido-6-p-methoxyphenyl-4-oxohexanoic acid and L-proline amide were used as starting materials. There were thus obtained two isomers of 1-(5-benzamido-6-p-methoxyphenyl-4-oxohexanoyl)pyrrolidine-(S)-2-carboxamide, a less polar isomer (Compound No. 282A) and a more polar isomer (Compound No. 282B), the isomers being separated by the chromatographic purification step.

Example 24

The process described in Example 20 was repeated except that (R,S)-5-N-methylbenzamido-4-oxo-6-phenylhexanoic acid and L-proline t-butyl ester were used as starting materials. There was thus obtained N-[(R,S)-5-N-methylbenzamido-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No 216), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The hexanoic acid used as starting material was obtained as follows:-

Methyl trifluoromethanesulphonate (0.8 ml.) was added to a solution of 4-benzyl-2-phenyl-4-(3-methoxycarbonylpropionyl)-oxazol-5(4H)-one (1.46 g., m.p. 93-94°C.; prepared from 3-methoxycarbonylpropionyl chloride, 2-phenyloxazol-5(4H)-one and benzyl bromide by the general procedure described in the second and third parts of Example 20) in methylene chloride (10 ml.) and the mixture was heated under reflux under an atmosphere of argon for 10 hours and then evaporated to dryness under reduced pressure. The residue was dissolved in a mixture of methylene chloride (21 ml.) and acetic acid (7 ml.), 4-dimethylaminopyridine (0.2 g.) was added and the mixture was heated under reflux for 30 minutes and then evaporated to dryness. The residue

was dissolved in methylene chloride and the solution was washed successively with saturated aqueous sodium bicarbonate solution, 10% w/v aqueous hydrochloric acid, water and saturated aqueous sodium chloride solution, dried over sodium sulphate and evaporated to dryness. There was thus obtained (R,S)-5-N-methylbenzamido-4-oxo-6-phenylhexanoic acid as an oil which was used without further purification.

Example 25

A solution of N-[(R,S)-5-benzamido-6-p-nitrophenyl-4-oxohexanoyl]-L-proline t-butyl ester (Compound No. 206; Example 23; 9.1 g.) in ethanol (350 ml.) was shaken with hydrogen at laboratory temperature and atmospheric pressure for 5 hours in the presence of a 10% palladium-on-charcoal catalyst (0.5 g.). The mixture was filtered, the filtrate was evaporated to dryness and the residue was stirred with diethyl ether. The mixture was filtered and there was thus obtained as solid residue Isomer B of N-6-p-aminophenyl-5-benzamido-4-oxohexanoyl)-L-proline t-butyl ester (Compound No. 217B), m.p. °C., $[\alpha]_D^{25} - 3.9^\circ$ (C=1 in methanol).

The ethereal filtrate was evaporated to dryness under high vacuum, and there was thus obtained as an oil Isomer A of N-[6-p-aminophenyl-5-benzamido-4-oxohexanoyl)-L-proline t-butyl ester (Compound No. 217A) $[\alpha]_D^{25} - 82.6^\circ$ (C=1 in methanol).

Example 26

Acetyl chloride (0.0785 ml.) was added dropwise to a stirred solution of Isomer A of N-(6-p-aminophenyl-5-benzamido-4-oxohexanoyl)-L-proline t-butyl ester (Compound No. 217A; Example 25; 0.493 g.) and triethylamine (0.1384 ml.) in tetrahydrofuran (7 ml.) which was cooled to 0°C under an atmosphere of argon, and the mixture was stirred for 1 hour and then poured onto a silica gel column (10 g.). The column was eluted with a 19:1v/v mixture of methylene chloride and methanol and the appropriate fractions collected and evaporated to dryness. There was thus obtained Isomer A of N-(6-p-acetamidophenyl-5-benzamido-4-oxohexanoyl)-L-proline t-butyl ester (Compound No. 218A), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The process described above was repeated using methanesulphonyl chloride in place of acetyl chloride. There was thus obtained N-(5-benzamido-6-p-methanesulphonamido-4-oxohexanoyl)-L-proline t-butyl ester (Compound No. 219A), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

By using trifluoromethanesulphonylchloride there was similarly obtained N-(5-benzamido-6-p-trifluoromethanesulphonamido-4-oxohexanoyl)-L-proline t-butyl ester (Compound No. 220A).

Example 27

The process described in Example 1 was repeated except that (R,S)-5-p-cyanobenzamido-(R,S)-2-methyl-4-oxo-6-p-tolyhexanoic acid and L-proline t-butyl ester were used as starting materials. There was thus obtained as an oil N-[(R,S)-5-p-cyanobenzamido-(R,S)-2-methyl-4-oxo-6-p-tolyhexanoyl]-L-proline t-butyl ester (Compound No. 221), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The (R,S)-5-p-cyanobenzamido-(R,S)-2-methyl-4-oxo-6-p-tolyhexanoic acid used as starting material was obtained as follows:-

Diethyl acetamidomalonate (108.5g) was slowly added to a stirred solution of sodium (12 g.) in ethanol (400 ml.) and the mixture was stirred at laboratory temperature for 30 minutes. Sodium iodide (5 g.) and p-methylbenzyl bromide (96 g.) were added and the mixture was stirred and heated under reflux for 16 hours, cooled and evaporated to dryness under reduced pressure. The residue was partitioned between water (250 ml.) and ethyl acetate (500 ml.) and the organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated to dryness. The residue was stirred with a 4:1 v/v mixture of petroleum ether (b.p. 40-60°C) and diethyl ether and the mixture was filtered. There was thus obtained ethyl 2-acetamido-2-ethoxycarbonyl-3-p-tolylpropionate, m.p. 111-113°C.

A stirred suspension of the above diester (127 g.) in 10% aqueous sodium hydroxide solution (600 ml.) was heated under reflux for 4 hours, cooled, acidified with aqueous 3N-hydrochloric acid, reheated under reflux for 1 hour, cooled to 0°C., kept at that temperature for 72 hours and then filtered.

There was thus obtained as solid residue (±)-2-acetamido-3-p-tolylpropionic acid.

A mixture of the above acid (35 g.) and acetic anhydride (300 ml.) was stirred at 100°C for 40 minutes,
5 cooled and the excess of acetic anhydride was removed by evaporation under reduced pressure. The residue was distilled and there was thus obtained 2-methyl-4-p-tolyloxazol-5(4H)-one, b.p. 116-120°C/0.2 mm.Hg.

This oxazolone was reacted with 3-methoxy-
10 pentanoylbutyryl chloride by a similar process to that described in the second part of Example 1 to give methyl (R,S)-5-acetamido-(R,S)-2-methyl-4-oxo-6-p-tolylhexanoate, and this was hydrolysed with aqueous 6N hydrochloric acid and acylated with p-cyanobenzoyl chloride
15 by a similar procedure to that described in the last part of Example 9. There was thus obtained (R,S)-5-p-cyanobenzamido-(R,S)-2-methyl-4-oxo-6-p-tolylhexanoic acid which was used without further purification.

Example 28

20 The process described in Example 27 was repeated except the corresponding 5-p-acetamidobenzamido-hexanoic acid was used as starting material in place of the 5-p-cyanobenzamido-hexanoic acid. There was thus obtained as an oil N-[(R,S)-5-p-acetamidobenzamido-(R,S)-methyl-
25 4-oxo-6-p-tolylhexanoyl]-L-proline t-butyl ester (Compound No. 222), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The starting material was obtained by a similar procedure to that described in Example 27 except that
30 the final acylation stage was carried out as follows:-

N-Methylmorpholine (0.77 ml.) and isobutyl chloroformate (0.91 ml.) were added to a stirred solution of p-acetamidobenzoic acid (1.25 g.) in tetrahydrofuran (40 ml.) which was cooled to -20°C. under an atmosphere
35 of argon, and the stirred mixture was allowed to warm up

to laboratory temperature during 1 hour and was then cooled to 0°C. (R,S)-5-Amino-(R,S)-2-methyl-4-oxo-6-p-tolyhexanoic acid (2 g.) and then triethylamine (1.95 ml.) were added and the mixture was stirred
5 at laboratory temperature for 16 hours, and then filtered, and the filtrate was evaporated to dryness under reduced pressure. The residue was partitioned between ethyl acetate (50 ml.) and aqueous 0.1 N-hydrochloric acid (25 ml.) and the organic phase was dried
10 over magnesium sulphate and evaporated to dryness. The residue was purified by chromatography on a silica gel column using a 10:10:1 v/v/v mixture of toluene, ethyl acetate and acetic acid as eluant, and there was thus obtained (R,S)-5-p-acetamidobenzamido-
15 (R,S)-2-methyl-4-oxo-6-p-tolyhexanoic acid.

Example 29

Oxalyl chloride (1.0 ml.) and dimethylformamide (0.25 ml.) were added to a stirred solution of N-[3-carboxy-(R,S)-2-methylpropionyl]-L-proline t-butyl
20 ester (2.86 g.) in dry methylene chloride (50 ml.) which was cooled to -70°C. under an atmosphere of argon, and the mixture was stirred at -70°C for 2 hours, then at 0-50°C for 2 hours and finally at laboratory temperature for 1 hour, and then evaporated to dryness under
25 reduced pressure. Toluene was added and the mixture was evaporated to dryness under reduced pressure. A solution of the acid chloride thus obtained in dry tetrahydrofuran (2 ml.) was added to a stirred solution of 2-phenyloxazol-5(4H)-one (1.47 g.), 4-dimethylaminopyridine
30 (0.08 g.) and triethylamine (2.54 ml.) in dry tetrahydrofuran (20 ml.) which was cooled to -40°C under an atmosphere of argon, at such a rate that the temperature of the mixture did not exceed -35°C. The mixture was stirred at -35°C. for 1 hour, then at laboratory
35 temperature for 16 hours, benzyl bromide (1.19 ml.)

was added and the mixture was stirred at laboratory temperature for 48 hours. Saturated aqueous sodium carbonate solution (4 ml.) was added and the mixture was stirred at laboratory temperature for 2 hours
5 and then neutralised to pH 7 with aqueous 2N-hydrochloric acid. The organic solvents were removed by evaporation under reduced pressure and the aqueous residue was extracted 4 times with ethyl acetate (50 ml. each time). The combined extracts were washed
10 successively twice with saturated aqueous oxalic acid solution (50 ml. each time), twice with saturated aqueous sodium bicarbonate solution (50 ml. each time) and once with saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated to dryness under
15 reduced pressure. The residue was purified by chromatography on a silica gel column using a 3:1 v/v mixture of methylene chloride and ethyl acetate as eluant. There was thus obtained, as a foam, N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-
20 L-proline t-butylester (Compound No. 6), identical with that hereinbefore described in Example 2.


The N-[3-carboxy-(R,S)-2-methylpropionyl]-L-proline t-butyl ester used as starting material was obtained as follows:-

25 A solution of dicyclohexylcarbodi-imide (4.8 g.) in methylene chloride (100 ml.) was added during 30 minutes to a stirred suspension of N-hydroxybenzotriazole (40.5 g.) and 3-methoxycarbonyl-(R,S)-2-methylpropionic acid (43.8 g.) in methylene chloride (1000 ml.) which
30 was cooled to 0°C. under an atmosphere of argon, and the mixture was then stirred at laboratory temperature for 1 hour and re-cooled to 0°C. A solution of L-proline t-butyl ester (51.3 g.) in methylene chloride (100 ml.) was added and the mixture was stirred at laboratory
35 temperature for 16 hours and then filtered. The filtrate was evaporated to dryness, the residue was dissolved

in diethyl ether (500 ml.) and the mixture was filtered. The filtrate was washed successively five times with aqueous 2N-hydrochloric acid (50 ml. each time) four times with saturated aqueous sodium carbonate solution (100 ml. each time) and twice with saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated to dryness under reduced pressure. Aqueous 2N-sodium hydroxide solution (113 ml.) was added to a solution of the methyl ester thus obtained (61.8 g.) in methanol (325 ml.) and the mixture was stirred at laboratory temperature for 3.5 hours, neutralised with aqueous N-hydrochloric acid and the methanol was removed by evaporation under reduced pressure. Saturated aqueous sodium carbonate solution was added to the aqueous residue and the mixture was washed 3 times with diethyl ether (50 ml. each time). The aqueous solution was then acidified to pH 2 with aqueous N-hydrochloric acid and extracted 6 times with ethyl acetate (50 ml. each time). The combined extracts were washed twice with saturated aqueous sodium chloride solution (50 ml. each time), dried over magnesium sulphate and evaporated to dryness under reduced pressure. There was thus obtained N-[3-carboxy-(R,S)-2-methylpropionyl]-L-proline t-butyl ester as an oil which was used without further purification.

Example 30

The process described in Example 29 was repeated except that the appropriate bromide was used in place of benzyl bromide. There were thus obtained as foams, the compounds described in the following table, the structures of which were all confirmed by elemental analysis and proton magnetic resonance spectroscopy:-



R^3	Compound No.
<u>p</u> -methylbenzyl	92
<u>m</u> -methylbenzyl	223
<u>p</u> -chlorobenzyl	224
<u>m</u> -chlorobenzyl	225
<u>p</u> -methoxybenzyl	93
<u>p</u> -nitrobenzyl	226
<u>p</u> -trifluoromethylbenzyl	227
<u>p</u> -cyanobenzyl	91
4-biphenylmethyl	228
<u>p</u> -t-butylbenzyl	229
3-phenylprop-2-enyl	230
prop-2-enyl	231
2-methylprop-2-enyl	232

Example 31

A suspension of a 10% palladium-on-charcoal catalyst (0.03 g.) in a solution of N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-8-phenylocta-7-enoyl]-L-proline t-butyl ester (Compound No. 230; 0.94 g.) in ethyl acetate (10 ml.) was stirred in an atmosphere of hydrogen for 1 hour and then filtered. The filtrate was evaporated to dryness under reduced pressure and there was thus obtained N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-8-phenyloctanoyl]-L-proline t-butyl ester (Compound No. 233).


The process described above was repeated using N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-octa-7-enoyl]-L-proline t-butyl ester (Compound No. 231) or

N-[(R,S)-5-benzamido-(R,S)-2,7-dimethyl-4-oxo-octa-7-enoyl]-L-proline t-butyl ester (Compound No. 232) as starting material, and there was thus obtained, respectively, N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-octanoyl]-L-proline t-butyl ester (Compound No. 234) or N-[(R,S)-5-benzamido-(R,S)-2,7-dimethyl-4-oxo-octanoyl]-L-proline t-butyl ester (Compound No. 235).

All three compounds described above are non-crystalline foams the structures of which were confirmed by elemental analysis and spectroscopic procedures.

Example 32

The process described in Example 5 was repeated using the t-butyl esters described in Examples 8, 2, 22, 23, 24, 25, 26, 27, 28, 30 and 31 as starting materials, and there were thus obtained the acids described in the following table, all of which were oils the structures of which were confirmed by elemental analysis and spectroscopic procedures:-



Starting Material Compound No.	R ¹	R ³	R ⁴	Acid Compound No.
17	4-acetamidophenyl	benzyl	H	37
18	4-methoxyphenyl	benzyl	H	38
19	2-naphthyl	benzyl	H	39
20	β-phenylethyl	benzyl	H	40
41	β-benzoylethyl	benzyl	H	141
43	benzyloxy	benzyl	H	143
91	phenyl	p-cyanobenzyl	methyl	191
92	phenyl	p-methylbenzyl	methyl	192

Continued...

Continuation...

Starting Material Compound No.	R ¹	R ³	R ⁴	Acid Compound No.
93	phenyl	<u>p</u> -methoxybenzyl	methyl	193
95	phenyl	<u>p</u> -cyanobenzyl	H	195
97	phenyl	<u>m</u> -methylbenzyl	H	197
99	phenyl	<u>o</u> -methylbenzyl	H	199
100	phenyl	<u>p</u> -chlorobenzyl	H	200
201	phenyl	<u>p</u> -fluorobenzyl	H	301
203	phenyl	<u>o</u> -bromobenzyl	H	303
204	phenyl	3,4-dichlorobenzyl	H	304
205	phenyl	<u>p</u> -methoxybenzyl	H	305
206	phenyl	<u>p</u> -nitrobenzyl	H	306
207	phenyl	<u>p</u> -methylbenzyl	H	307
208	phenyl	<u>m</u> -cyanobenzyl	H	308
209	phenyl	<u>p</u> -trifluoromethyl- benzyl	H	309
210	phenyl	β-phenylethyl	H	310
211	phenyl	3-phenylpropyl	H	311
212	phenyl	3-phenylprop-2-enyl	H	312
213	phenyl	naphth-1-ylmethyl	H	313
214	phenyl	naphth-2-ylmethyl	H	314
215	phenyl		H	315
216	phenyl (<u>N</u> -methyl)	benzyl	H	316
217	phenyl	<u>p</u> -aminobenzyl	H	317
217A	phenyl	<u>p</u> -aminobenzyl	H	317A
(Isomer A) 218A	phenyl	<u>p</u> -acetamidobenzyl	H	318A

Continued...

Starting Material Compound No.	R ¹	R ³	R ⁴	Acid Compound No.
219A (Isomer A)	phenyl	p-methanesulphonamido-benzyl	H	319A
220A	phenyl	p-trifluoromethane-sulphonamidobenzyl	H	320A
221	p-cyanophenyl	p-methylbenzyl	methyl	321
222	p-acetamidophenyl	p-methylbenzyl	methyl	322
223	phenyl	m-methylbenzyl	methyl	323
224	phenyl	p-chlorobenzyl	methyl	324
225	phenyl	m-chlorobenzyl	methyl	325
226	phenyl	p-nitrobenzyl	methyl	326
227	phenyl	p-trifluoromethyl-benzyl	methyl	327
228	phenyl	4-biphenylmethyl	methyl	328
229	phenyl	p-t-butylbenzyl	methyl	329
230	phenyl	3-phenylprop-2-enyl	methyl	330
231	phenyl	prop-2-enyl	methyl	331
232	phenyl	2-methylprop-2-enyl	methyl	332
233	phenyl	3-phenylpropyl	methyl	333
234	phenyl	n-propyl	methyl	334
235	phenyl	isobutyl	methyl	335
276	phenyl	o-chlorobenzyl	methyl	376
61A	phenyl-CH ₂ - CH (NHCOOCH ₂ C ₆ H ₅)-	benzyl	H	161A
62A	CH ₃ CH (NHCO- OCH ₂ C ₆ H ₅)-	benzyl	H	162A
63A	phenyl-NH-	benzyl	H	163A
(161A)	phenyl-CH ₂ CH (NH ₂)-	benzyl	H	164A*
278	p-nitrophenyl	benzyl	H	378
279	p-chlorophenyl	benzyl	H	379


* Prepared from Compound No. 161A by hydrogenolysis of the benzyloxy-carbonyl group by a similar process to that described in Example 12.

Example 33

N,N'-Dicyclohexylcarbodiimide (0.93 g.) was added to a stirred solution of N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 26; 2.09 g.), 4-dimethylaminopyridine (0.06 g.) and methanol (2.0 ml.) in tetrahydrofuran (25 ml.) which was cooled to 0°C., and the mixture was stirred at laboratory temperature for 18 hours, recooled to 0°C. and filtered. The filtrate was evaporated to dryness under reduced pressure, the residue was dissolved in methylene chloride and the solution was washed successively with 1% w/v aqueous citric acid solution, water, 1% w/v aqueous sodium bicarbonate solution and water, dried over magnesium sulphate and evaporated to dryness under reduced pressure. The residue was purified by chromatography on a silica gel column using a 1:1 v/v mixture of methylene chloride and ethyl acetate as eluant. There was thus obtained, as a foam, N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (Compound No. 236), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The process described above was repeated except that the appropriate N-acyl-L-proline (Compound No. 26, 27 or 27A), and the appropriate alcohol were used as starting materials. There were thus obtained the compounds described in the following table, the structures of which were all confirmed by elemental analysis and spectroscopic procedures:-

30



R ⁴	R ⁷	Compound No
methyl	isopropyl	237
methyl	n-pentyl	238
methyl	β -morpholinoethyl	239
methyl	β -dimethylaminoethyl	240
H(Isomer A)	isopropyl	241A
H(Mixed Isomers)	p-chlorophenyl	242
H(Isomer A)	methyl	283A

There was also similarly prepared, from
N-[(R,S)-5-benzamido-4-oxo-6-phenylhexanoyl]-L-proline
 (Compound No. 27) and thiophenol, N-[(R,S)-5-benzamido-
 5 4-oxo-6-phenylhexanoyl]-L-proline thiophenyl ester
 (Compound No. 243).


Example 34

Chloromethyl pivaloate (0.66 ml.) was added
 to a solution of N-[(R,S)-5-benzamido-4-oxo-6-phenyl-
 10 hexanoyl]-L-proline (Compound No. 27; 0.71 g.) and
 triethylamine (0.45 ml.) in ethyl acetate (20 ml.) which
 had been stirred at laboratory temperature for 30
 minutes, and the mixture was then heated under reflux
 for 18 hours and evaporated to dryness under
 15 reduced pressure. The residue was purified by chrom-
 atography on a silica gel column using a 3:1 v/v
 mixture of methylene chloride and ethyl acetate as eluant.
 There was thus obtained N-[(R,S)-5-benzamido-4-oxo-6-
 phenylhexanoyl]-L-proline pivaloyloxymethyl ester,
 20 (Compound No. 244) the structure of which was confirmed
 by elemental analysis and spectroscopic procedures.

Example 35

The process described in Example 1 was
 repeated using (R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-
 25 6-phenylhexanoic acid and the appropriate L-proline
 derivative as starting materials, and there were thus

obtained as foams the compounds described in the following table, the structures of which were all confirmed by elemental analysis and spectroscopic procedures:-



$-Q^3R^{10}$	Compound No.
$-\text{COOCH}_2\text{C}_6\text{H}_5$	245
$-\text{CONH}_2$	246
$-\text{CH}_2\text{OH}$	247

5 Example 36

N-[(R,S)-5-Benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (Compound No. 236, Example 33, 0.5 g.) was dissolved in saturated methanolic ammonia solution (20 ml.) and the mixture was kept at laboratory temperature for 10 days and then evaporated to dryness under reduced pressure. The residue was purified by chromatography on a silica gel column using a 19:1 v/v mixture of methylene chloride and methanol as eluant. There was thus obtained as a foam 1-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-pyrrolidine-(S)-2-carboxamide (Compound No. 246), the structure of which was confirmed by elemental analysis and spectroscopic procedures. The compound was identical to that obtained in Example 35.

Example 37

N,N'-Dicyclohexylcarbodi-imide (0.47 g.)
was added to a stirred solution of N-[(R,S)-benzamido-
(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline
5 (Compound No. 26; 1.0 g.) 1-hydroxybenzotriazole (0.3 g.)
and β -dimethylaminoethylamine (1.0 ml.) which was
cooled to 0°C, and the mixture was stirred at laboratory
temperature for 16 hours, recooled to 0°C, and
filtered. The filtrate was evaporated to dryness under
10 reduced pressure, the residue was dissolved in methylene
chloride (100 ml.) and the solution was washed with 1%
aqueous sodium bicarbonate solution and then with water,
dried over magnesium sulphate and evaporated to dryness
under reduced pressure. The residue was purified by
15 chromatography on a silica gel column using a 9:1 v/v
mixture of methylene chloride and methanol as eluant,
and there was thus obtained, as a foam, 1-[(R,S)-benzamido-
(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]pyrrolidine-(S)-
2-(N- β -dimethylaminoethyl)carboxamide (Compound No. 248),
20 the structure of which was confirmed by elemental
analysis and spectroscopic procedures.


The process described above was repeated except
that a 33% w/v solution of ethylamine in ethanol was
used in place of β -dimethylaminoethylamine. There
25 was thus obtained 1-[(R,S)-5-benzamido-(R,S)-2-methyl-
4-oxo-6-phenylhexanoyl]pyrrolidine-(S)-2-N-ethylcarboxamide
(Compound No. 249).

Example 38

A solution of diazomethane in diethyl ether
30 was added to a solution of N-[(R,S)-5-benzamido-(R,S)-
2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound
No. 26; 0.11 g.) in diethyl ether (2 ml.) until the
yellow colour persisted. The mixture was then evaporated
to dryness by blowing a stream of argon through it, and
35 there was thus obtained as an oil N-[(R,S)-5-benzamido-
(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl

ester (Compound No. 236), identical to that prepared according to Example 33.

The process described above was repeated using the appropriate acid prepared according to Example 32, and there were thus obtained the esters described in the following table:-



R^1	R^3	Compound No.
phenyl	3-phenylprop-2-enyl	250
phenyl	3-phenylpropyl	251
p-cyanophenyl	p-methylbenzyl	252
p-acetamido-phenyl	p-methylbenzyl	253
phenyl	p-methylbenzyl	254
phenyl	m-methylbenzyl	255
phenyl	p-chlorobenzyl	256
phenyl	m-chlorobenzyl	257
phenyl	o-chlorobenzyl	258
phenyl	p-cyanobenzyl	259
phenyl	p-methoxybenzyl	260
phenyl	p-nitrobenzyl	261
phenyl	p-trifluoromethylphenyl	262

Example 39

Silica gel (Merck Kieselgel 60, 70-230 mesh ASTM: 450 g.) was deactivated with water (50 ml.) ethyl acetate (25 ml.) and toluene (25 ml.) and the mixture

- 66 -

was allowed to stand for 16 hours and then packed into a tube of 5 mm. diameter. N-[(R,S)-5-Benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 6; 3 g.) was absorbed onto silica gel (6 g.) and the mixture was placed on top of the column which was then developed with a 1:1 v/v mixture of ethyl acetate and toluene. The column was dried and cut up into bands from which were separately isolated two isomers of the ester (isomeric at the 2-carbon atom of the hexanoyl chain). The less polar isomer (Compound No. 6A) was 10 times more active as an inhibitor of angiotensin converting enzyme than the more polar isomer (Compound No. 6B).


The less polar isomer (1.5 g.) was reapplied to a similar column to that described above which consisted of 1500 g. of silica gel and again separate bands of the dried and cut up column yielded two isomers (isomeric at the 5-carbon atom of the hexanoyl chain). The more polar isomer (Compound No. 6C) was 100 times more active as an inhibitor of angiotensin converting enzyme than the less polar isomer (Compound No. 6D).

A mixture of a single isomer at the 5-carbon atom (0.2 g.) dissolved in dimethoxyethane (15 ml.) and aqueous 2N-sodium hydroxide solution was kept at laboratory temperature for 36 hours and neutralised with aqueous N-hydrochloric acid. The organic material was isolated by conventional procedures and found to be a mixture of isomers at the 5-carbon atom. These could be separated as described above and thus it is possible to convert a less active isomer (for example Compound No. 6D) into a more active isomer (for example Compound No. 6C).

The t-butyl ester Compound No. 6C was converted into the free acid by the process described in Example 5, and there was thus obtained one isomer of N-(5-benzamido-2-methyl-4-oxo-6-phenylhexanoyl)-L-proline (Compound No. 26C.)

Example 40

The process described in Example 1 was repeated except that (R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoic acid and the appropriate amino acid methyl ester were used as starting materials. There were thus obtained the compounds described in the following table, most of which were oils or low-melting solids, all of which were purified by chromatography on silica gel, and the structures of all of which were confirmed by elemental analysis and spectroscopic procedures:



R ⁵	R ⁶	R ¹⁶	Compound No.
-(CH ₂) ₂ -		H	263 (Note 1)
-(CH ₂) ₄ -		H	264
-(CH ₂) ₅ -		H	265
-CH ₂ CHOHCH ₂ -		H	{ 266 (more polar isomer) } (Note 2) { 267 (less polar isomer) }
H	CH ₃	CH ₃	268
H	-(CH ₂) ₄ -		269 (m.p. 121-124°C.)
H	Indol-3-yl-methyl	H	294 (Note 3)


Note 1 The amino acid ester used was methyl azetidine-(S)-2-carboxylate.

Note 2. The amino acid ester used was (R)-4-hydroxy-L-proline methyl ester.

Note 3 The amino acid ester used was L-tryptophan methyl ester.

5 Example 41

The process described in Example 7 was repeated using the appropriate methyl ester described in Example 40. There were thus obtained the acids shown in the following table:-



R ⁵	R ⁶	R ¹⁶	Compound No.
-(CH ₂) ₅ -	H		365
H	CH ₃	CH ₃	368
H	-(CH ₂) ₄ -		369 (m.p. 157-158°C.
H	Indol-3-yl-methyl	H	394

The structures of all these compounds were confirmed by elemental analysis and spectroscopic procedures.

Example 42

15 A solution of methyl thiazolidine-(S)-4-carboxylate (0.294 g.) and succinic anhydride (0.2 g.) in methylene chloride (2 ml.) was stirred at laboratory temperature for 2 hours, cooled to -30°C. and oxalyl chloride (0.27 g.) and dimethylformamide (1 drop) were added. The mixture was stirred at -15°C for 2 hours. and then evaporated
20 to dryness, the residue was dissolved in tetrahydrofuran (1.5 ml.) and the mixture was added during 5 minutes to

a stirred solution of 4-benzyl-2-phenyloxazol-5(4H)-one (0.5 g.), 4-dimethylaminopyridine (0.03 g.) and triethylamine (0.56 ml.) in tetrahydrofuran (4 ml.) which was cooled to -50°C . The mixture was stirred
5 for 2 hours at -40°C , then 40 hours at laboratory temperature, acetic acid (3 ml.) was added and the mixture was heated under reflux for 3 hours and then evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate and the
10 solution was washed successively with water, aqueous 2N-hydrochloric acid, saturated aqueous sodium chloride solution, saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated to dryness.
15 The residue was purified by chromatography on a silica gel column using a 1:1 v/v mixture of ethyl acetate and toluene as eluant, and there was thus obtained as a foam methyl N-[(R,S)-5-benzamido-4-oxo-6-phenylhexanoyl]-thiazolidine-(S)-4-carboxylate, (Compound No. 270) the
20 structure of which was confirmed by elemental analysis and spectroscopic procedures.

Example 43

The process described in Example 7 was repeated using Compound No. 270 (Example 42) as starting material.
25 There was thus obtained N-[(R,S)-5-benzamido-4-oxo-6-phenylhexanoyl]thiazolidine-(S)-4-carboxylic acid (Compound No. 370).

Example 44

N-Methylmorpholine (0.31 g.) was added to a
30 stirred solution of (R,S)-5-benzamido-(R,S)-2-methyl 4-oxo-6-phenylhexanoic acid (1.02 g.), L-homoserine lactone hydrochloride (0.42 g.), N-hydroxybenzotriazole (0.45 g.) and dicyclohexylcarbodi-imide (0.65 g.) in dimethylformamide (8 ml.) which was cooled to 0°C ., and the
35 mixture was stirred at 10°C . for 3 hours and then at laboratory temperature for 16 hours, and then filtered.

The filtrate was evaporated to dryness under reduced pressure, the residue was partitioned between ethyl acetate and aqueous 2N-hydrochloric acid and the organic layer was separated, washed successively with aqueous 2N-hydrochloric acid, saturated aqueous sodium carbonate solution (twice) and saturated aqueous sodium chloride solution, dried and evaporated to dryness. The residue was purified by chromatography on a silica gel column using a 19:1 v/v mixture of chloroform and methanol as eluant, and there was thus obtained N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-homoserine lactone (Compound No. 271), m.p. 104-109°C.

Example 45

Hydroxylamine hydrochloride (1.0 g.) and pyridine (1 ml.) were added to a solution of N-[(R,S)-5-benzamido-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 7; 1.0 g.) in ethanol (20 ml.) and the mixture was heated under reflux for 40 minutes and then evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (75 ml.) and the solution was washed successively with 30 ml. each of aqueous 5% hydrochloric acid, water, saturated aqueous sodium bicarbonate solution and saturated sodium chloride solution, dried over sodium sulphate and evaporated to dryness. There was thus obtained as oily residue N-[(R,S)-5-benzamido-4-hydroxyimino-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 272), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

Example 46

The process described in Example 5 was repeated using Compound No. 272 (Example 45) as starting material. There was thus obtained N-[(R,S)-5-benzamido-4-hydroxyimino-6-phenylhexanoyl]-L-proline (Compound No. 372).

Example 47

The process described in Example 14 was repeated except that L-proline methyl ester was used in place of L-proline t-butyl ester. There was thus obtained
5 as an oil N-[(R,S)-5-benzyloxycarbonylamino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (Compound No. 273), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

Example 48


10 S-Thiobenzoylthioglycollic acid (0.33 g.) was added to a stirred solution of N-[(R,S)-5-amino-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline methyl ester (Compound No. 67; Example 17; 0.54 g.) and triethyl-
15 amine (0.2 ml.) in pyridine (9 ml.) and the mixture was stirred at laboratory temperature for 40 hours and then poured into aqueous 2N-sulphuric acid. The mixture was extracted with ethyl acetate and the extract was washed with dilute aqueous sodium bicarbonate solution, dried over magnesium sulphate and evaporated to dryness.
20 The residue was purified by chromatography on a silica gel column (18 g.) using an 11:8:1 v/v/v mixture of toluene, ethyl acetate and methanol as eluant. There was thus obtained as an oil N-[(R,S)-2-methyl-4-oxo-6-phenyl-(R,S)-5-thiobenzamidohexanoyl]-L-proline
25 methyl ester (Compound No. 274), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

Example 49

The process described in Example 33 was
30 repeated using Isomer A of N-(5-p-cyanobenzamido-4-oxo-6-phenylhexanoyl)-L-proline (Compound No. 145A, Example 13) and methanol as starting materials, and there was thus obtained as an oil Isomer A of N-(5-p-cyanobenzamido-4-oxo-6-phenylhexanoyl)-L-proline methyl ester (Compound
35 No. 284A), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

Example 50

The process described in Example 1 was repeated except that (R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoic acid and the appropriate amino acid ethyl ester were used as starting materials. There were thus obtained the compounds described in the following table, all of which were oils, all of which were purified by chromatography on silica gel, and the structures of all of which were confirmed by elemental analysis and spectroscopic procedures:-



R ⁵	R ⁶	Compound No.
-CH ₂ CH ₂ SCH ₂ -		285
-CH ₂ CH ₂ OCH ₂ -		286
-CH ₂ CH ₂ NCH ₂ -		287
CH ₃		
-CH ₂ CH=CH-		288 (Note 1)
-CH ₂ SCH ₂ -		289 (Notes 1, 2)
CH ₃	H	290 (Note 2)

Note 1 The L-amino acid ethyl ester was used as starting material.

Note 2 A mixed anhydride procedure using isobutyl chloroformate (similar to that described in Example 19)

was used instead of dicyclohexylcarbodiimide to couple the acid and the aminoacid ester.

Example 51

The process described in Example 45 was repeated except that methoxyamine or benzyloxyamine were used in place of hydroxylamine. There were thus obtained N-[(R,S)-5-benzamido-4-methoxyimino-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No.291) and N-[(R,S)-5-benzamido-4-benzyloxyimino-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 292), the structures of which were confirmed by elemental analysis and spectroscopic procedures.

Example 52

The process described in Example 46 was repeated using Compounds Nos.291 and 292 (Example 51) as starting materials. There were thus obtained N-[(R,S)-5-benzamido-4-methoxyimino-6-phenylhexanoyl]-L-proline (Compound No. 391) and N-[(R,S)-5-benzamido-4-benzyloxyimino-6-phenylhexanoyl]-L-proline (Compound No. 392).

Example 53

The process described in Example 1 was repeated except that (R,S)-5-benzamido-(R,S)-3-methyl-4-oxo-6-phenylhexanoic acid and L-proline t-butyl ester were used as starting materials. There was thus obtained N-[(R,S)-5-benzamido-(R,S)-3-methyl-4-oxo-6-phenylhexanoyl]-L-proline t-butyl ester (Compound No. 293).

This compound was converted to the free acid by the process described in Example 5, and there was thus obtained N-[(R,S)-5-benzamido-(R,S)-3-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 393).

The structures of both ester and acid were confirmed by elemental analysis and spectroscopic procedures.

The (R,S)-5-benzamido-(R,S)-3-methyl-4-oxo-6-phenylhexanoic acid used as starting material was obtained by a similar process to that described in the

second part of Example 1, using 3-methoxycarbonyl-2-methylpropionyl chloride and 4-benzyl-2-phenyloxazol-5(4H)-one as starting materials.

Example 54

5 The process described in Example 1 was repeated using 4-oxo-6-phenyl-(R,S)-5-p-toluenesulphonamido-hexanoic acid and L-proline t-butyl ester as starting materials. There was thus obtained N-[4-oxo-6-phenyl-(R,S)-5-p-toluenesulphonamido-hexanoyl]-L-proline t-butyl ester
10 (Compound No. 295).

 This compound was converted to the free acid by the process described in Example 5, and there was thus obtained N-[4-oxo-6-phenyl-(R,S)-5-p-toluenesulphonamido-hexanoyl]-L-proline (Compound No. 395).

15 The structures of both ester and acid were confirmed by elemental analysis and spectroscopic procedures.


 The 4-oxo-6-phenyl-(R,S)-5-p-toluenesulphonamido-hexanoic acid used as starting material
20 was obtained by a similar process to that described in the last two parts of Example 4, from p-toluenesulphonyl chloride and methyl (R,S)-5-amino-4-oxo-6-phenylhexanoate.

Example 55

25 Sodium borohydride (0.14 g.) was added to a solution of N-[(R,S)-5-benzamido-(R,S)-2-methyl-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 26; 0.412 g.) in methanol (10 ml.), and after 15 minutes the mixture was poured into water (50 ml.) The methanol was
30 removed by evaporation under reduced pressure, the aqueous residue was acidified to pH 3 with aqueous 2N-hydrochloric acid and the mixture was extracted with ethyl acetate. The extract was washed with water, dried and

evaporated to dryness and the residue was purified by chromatography on a silica gel column using an 11:7:1:1 v/v/v/v mixture of toluene: ethyl acetate: formic acid: methanol as eluant. There was thus obtained,
5 as an oil, N-[(R,S)-5-benzamido-(R,S)-4-hydroxy-(R,S)-2-methyl-6-phenylhexanoyl]-L-proline (Compound No. 396), the structure of which was confirmed by elemental analysis and spectroscopic procedures.

The process described above was repeated using
10 N-[(R,S)-5-benzamido-4-oxo-6-phenylhexanoyl]-L-proline (Compound No. 27) as starting material. There was thus obtained N-[(R,S)-5-benzamido-(R,S)-4-hydroxy-6-phenylhexanoyl]-L-proline (Compound No. 397.).



What we claim is:

1. An amide derivative of the formula:-



- wherein either R^1 is hydrogen, or alkyl of up to 15
 5 carbon atoms which is unsubstituted, or which bears
 one substituent selected from amino, benzyloxycarbonyl-
 amino, hydroxy, alkoxy, alkylthio and alkoxycarbonyl
 each of up to 5 carbon atoms, and aryl, aryloxy
 and arylthio substituents; or which bears two or three
 10 substituents one of which is aryl, another of which is
 aryl, hydroxy, amino, benzyloxycarbonylamino, trifluoro-
 methyl, aryloxy or alkoxy of up to 5 carbon atoms and the
 third of which, if present, is aryl or trifluoromethyl;
 or R^1 is aryl or, when Y is carbonyl or thio-
 15 carbonyl, is aryloxy, alkoxy or arylalkoxy wherein the
 alkoxy part has up to 5 carbon atoms;
 or R^1 is halogenoalkyl of up to 6 carbon atoms
 or is alkenyl, halogenoalkenyl or cycloalkyl each of up
 to 6 carbon atoms which is unsubstituted or which
 20 bears an aryl substituent;
 or R^1 is a substituent of the formula
 $R^8CONHCHR^9$ - or $R^8COCH_2CHR^9$ - wherein R^8 is alkyl or
 cycloalkyl each of up to 10 carbon atoms, or aryl
 and R^9 is hydrogen, or alkyl of up to 5 carbon atoms which
 25 is unsubstituted or which bears an aryl substituent, or
 R^9 is a group other than those stated above such that
 the compound H_2NCHR^9COOH would be a common amino acid;
 wherein R^2 is hydrogen, alkyl of up to 5 carbon atoms
 which is unsubstituted or which bears an aryl substituent,
 30 or aryl;
 wherein R^3 is alkyl or alkenyl each of up to 5 carbon
 atoms which is unsubstituted or which bears an aryl

substituent, or R^3 is aryl or indolylmethyl;
 wherein R^4 is hydrogen or alkyl of up to 5 carbon atoms
 which is unsubstituted or which bears an aryl substituent;
 wherein either R^5 is hydrogen or aryl, or alkyl of up
 5 to 5 carbon atoms which is unsubstituted or which bears
 an aryl substituent, or R^5 is joined together with R^6
 as defined below;

wherein either R^6 is hydrogen, aryl or hetero-
 cyclic, or alkyl of up to 5 carbon atoms which is
 10 unsubstituted or which bears a hydroxy, aryl or hetero-
 cyclic substituent;

or R^6 and R^5 are joined together to form
 alkylene or alkenylene of 2 to 5 carbon atoms; or an
 oxa, thia or aza-derivative of said alkylene or
 15 alkenylene; or a hydroxy-or oxo-substituted derivative
 of said alkylene or alkenylene; or R^6 and R^{16} , or R^6 ,
 R^{16} and R^5 , or R^6 and R^{10} are joined together as defined
 below;

wherein R^{16} is hydrogen or alkyl of up to 5
 20 carbon atoms;


or R^6 and R^{16} are joined together to form
 alkylene of 2 to 5 carbon atoms (that is, to form a
 spirocycloalkyl group);

or R^{16} together with the first carbon atom
 25 of R^6 form a double bond wherein R^6 is otherwise alkyl,
 or wherein R^6 is otherwise substituted alkyl as
 defined above, or wherein R^6 and R^5 are otherwise
 joined together as defined above (that is, so that R^5 ,
 R^6 and R^{16} together form alkylidene);

wherein Q is carbonyl (-CO-) or methylene (-CH₂-);
 and wherein either R^{10} is hydroxy, amino,
 aryloxy, arylthio, alkoxy, cycloalkoxy, alkylamino,
 dialkylamino, cyclic amino, hydroxyalkoxy, acyloxyalkoxy,
 aminoalkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, cyclic
 35 aminoalkoxy, aminoalkylamino, alkylaminoalkylamino,
 dialkylaminoalkylamino, cyclic aminoalkylamino or aryl-

alkoxy wherein each alkyl or alkoxy has up to 5 carbon atoms and wherein cyclic amino has up to 6 carbon atoms; or wherein R^{10} and R^6 are joined together such that R^{10} is oxygen (-O-) joined to the terminal carbon atom of R^6 when it is alkyl; wherein R^{11} is hydrogen or alkyl of up to 3 carbon atoms; wherein X is carbonyl (-CO-), hydroxymethylene (-CHOH-), thiocarbonyl (-CS-) or oximinomethylene (-C=N-OR²⁰ wherein R^{20} is hydrogen or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent); and wherein Y is carbonyl, thiocarbonyl, sulphonyl (-SO₂-) or amido (-NHCO-);

- or a salt thereof where appropriate.
2. An amide derivative as claimed in claim 1 wherein X, Y and Q are all carbonyl and R^2 and R^{11} are both hydrogen, or a salt thereof.
3. An amide derivative having the formula:-



wherein R^1 is alkyl of up to 15 carbon atoms which is unsubstituted or which bears an aryl, aryloxy or arylthio substituent, or R^1 is aryl or aryloxy, or R^1 is a substituent of the formula $R^8CONHCHR^9$ - or $R^8COCH_2CHR^9$ - wherein R^8 is alkyl or cycloalkyl each of up to 10 carbon atoms, or aryl, and R^9 is hydrogen, or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^9 is a group other than those stated above such that the compound

- $\text{H}_2\text{NCHR}^9\text{COOH}$ would be a common amino acid;
 wherein Y and R^2 have the meanings stated in claim 1;
 wherein R^3 is alkyl or alkenyl each of up to 5 carbon
 atoms which is unsubstituted or which bears an aryl
 5 substituent, or R^3 is aryl or indolylmethyl;
 wherein X is carbonyl, hydroxymethylene, thiocarbonyl
 or oximinomethylene ($>\text{C}=\text{N}-\text{OH}$);
 wherein R^4 is hydrogen or alkyl of up to 5 carbon atoms
 which is unsubstituted or which bears an aryl substituent;
 10 wherein either R^5 is hydrogen, aryl or alkyl of up to
 5 carbon atoms which is unsubstituted or which bears
 an aryl substituent, R^6 is hydrogen, alkyl of up to
 5 carbon atoms which is unsubstituted or which bears an
 aryl or heterocyclic substituent, or R^6 is heterocyclic
 15 or aryl, and R^{16} is hydrogen;
 or R^5 and R^6 are joined together to form
 alkylene or alkenylene of 2 to 4 carbon atoms; or an oxa,
 thia or aza-derivative of said alkylene or alkenylene;
 or R^6 , R^{16} and R^5 are joined together such that
 20 R^{16} together with the first carbon atom of R^6 form a
 double bond wherein R^6 and R^5 are otherwise joined together
 as defined above;
 and wherein R^7 is hydrogen or alkyl of up to 5 carbon atoms;
 or a salt thereof.
- 25 4. An amide derivative having the formula:-



- wherein R^1 is methyl, benzyl, β -phenylethyl, benzyloxy,
 phenoxymethyl, phenylthiomethyl, phenyl, tolyl, methoxy-
 phenyl, methylthiophenyl, monochlorophenyl, dichloro-
 30 phenyl, fluorophenyl, iodophenyl, nitrophenyl, cyano-
 phenyl, trifluoromethylphenyl, acetamidophenyl, acetyl-
 phenyl, methanesulphonylphenyl, biphenyl, naphthyl,
 benzamidomethyl, cyclopentanecarbonamidomethyl or
 β -benzoyl ethyl;


β -dimethylaminoethoxy or β -morpholinoethoxy;
or a salt thereof.

$$R^1CONHCHR^3COCH_2CHR^4CON$$


30 8. A salt of an amide derivative, claimed in any
of claims 1 to 7 wherein R¹⁰ is hydroxy which is an

alkali metal or alkaline earth metal salt, or an ammonium or dicyclohexylamine salt.


9. A process for the manufacture of an amide derivative or a salt thereof, claimed in any of claims 1 to 8, which comprises (a) the reaction of an acid of the formula:-



- wherein R^1 , R^2 , R^3 , R^4 , R^{11} , X and Y have the meanings stated in any of claims 1 to 5, or of a reactive derivative thereof, with an amine of the formula:-



- wherein R^5 , R^6 , R^{16} and Q have the meanings stated in any of claims 1 to 5 and wherein R^{12} has any of the meanings stated in claims 1 to 5 for R^{10} except those containing a free hydroxy or amino group; or
- (b) for the manufacture of an amide derivative wherein R^2 is hydrogen and X is carbonyl or thiocarbonyl, the reaction of an amine of the formula:




- wherein R^3 , R^4 , R^5 , R^6 , R^{11} , R^{12} , R^{16} , Q and X^1 have the meanings stated above, with a compound of the formula R^1-Y-Z^1 , wherein R^1 and Y have the meanings stated above and wherein Z^1 is a displaceable halogen, alkanesulphonyl or arensulphonyl group, or Z^1 is hydroxy (in which case the reaction is carried out in the presence of a carbodiimide or an alkyl chloroformate), or, when Y is amido, with a compound of the formula R^1NCO , or, when Y is thiocarbonyl, with a compound of the formula $R^1CS-SCH_2COOH$; or

(c) for the manufacture of an amide derivative wherein R^2 is hydrogen and X is a carbonyl, the reaction of a compound of the formula:-



- 5 wherein R^4 , R^5 , R^6 , R^{11} , R^{12} , R^{16} , and Q have the meanings stated above and Z^2 is a displaceable halogen atom, with a compound of the formula




- wherein R^1 and R^3 have the meanings stated above,
 10 followed by hydrolysis of the oxazolone ring;
 whereafter an amide derivative wherein R^2 is alkyl, arylalkyl or aryl (and R^{10} is R^{12}) may be obtained by reacting the corresponding amide derivative wherein R^2 is hydrogen (and R^{10} is R^{12}) with a compound of the
 15 formula R^2Z , wherein R^2 has the meaning stated above and Z is a displaceable halogen, alkanesulphonyl or arenesulphonyl group;
 or whereafter an amide derivative wherein R^3 is unsubstituted or substituted alkyl may be obtained by
 20 the hydrogenation of the corresponding compound wherein R^3 is unsubstituted or substituted alkenyl;
 or whereafter an amide derivative wherein R^{10} is other than hydroxy (that is, wherein-Q- R^{10} forms an ester or amide group) may be obtained from the corresponding
 25 acid wherein-Q- R^{10} is $-COOH$ by conventional means of ester or amide formation;
 or whereafter an amide derivative wherein Q is carbonyl and R^{10} is hydroxy may be obtained by the hydrolysis of the corresponding amide derivative wherein R^{10} is alkoxy, or, when R^{10} is

t-butoxy, by the acid-catalysed cleavage of said compound;

or whereafter an amide derivative wherein X is hydroxymethylene may be obtained by the reduction of the

- 5 corresponding amide derivative wherein X is carbonyl;
or whereafter an amide derivative wherein X is oximino-
methylene may be obtained by the reaction of the
corresponding amide derivative wherein X is carbonyl
with hydroxylamine or an O-substituted hydroxylamine
10 derivative.

10. A pharmaceutical composition comprising as
active ingredient at least one amide derivative, or a
salt thereof, claimed in any of claims 1 to 8, in
association with a pharmaceutically-acceptable diluent
15 or carrier therefor.




REGINALD PETER SLATCHER

AUTHORISED REPRESENTATIVE
General Authorisation No. 97

EUROPEAN APPLICATION NO.Amides of 4-oxo-5-amidohexanoic acid derivativesClaims for Austria

What we claim is:

1. A process for the manufacture of an amide derivative of the formula:-



wherein either R^1 is hydrogen, or alkyl of up to 15
5 carbon atoms which is unsubstituted, or which bears
one substituent selected from amino, benzyloxycarbonyl-
amino, hydroxy, alkoxy, alkylthio and alkoxycarbonyl
each of up to 5 carbon atoms, and aryl, aryloxy and
arylthio substituents; or which bears two or three
10 substituents one of which is aryl, another of which is
aryl, hydroxy, amino, benzyloxycarbonylamino, trifluoro-
methyl, aryloxy or alkoxy of up to 5 carbon atoms and
the third of which, if present, is aryl or trifluoro-
methyl;

15 or R^1 is aryl or, when Y is carbonyl or thio-
carbonyl, is aryloxy, alkoxy or arylalkoxy wherein the
alkoxy aprt has up to 5 carbon atoms;

or R^1 is halogenoalkyl of up to 6 carbon atoms
or is alkenyl, halogenoalkenyl or cycloalkyl each of up
20 to 6 carbon atoms which is unsubstituted or which bears
an aryl substituent;

or R^1 is a substituent of the formula $R^8CONHCHR^9-$
or $R^8COCH_2CHR^9-$ wherein R^8 is alkyl or cycloalkyl each
of up to 10 carbon atoms, or aryl and R^9 is hydrogen, or
25 alkyl of up to 5 carbon atoms which is unsubstituted or
which bears an aryl substituent, or R^9 is a group other
than those stated above such that the compound H_2NCHR^9COOH
would be a common amino acid; wherein R^2 is hydrogen;

alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or aryl;
wherein R^3 is alkyl or alkenyl each of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^3 is aryl or indolylmethyl;
5 wherein R^4 is hydrogen or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent; wherein either R^5 is hydrogen or aryl, or alkyl of up to 5 carbon atoms which is unsubstituted or
10 which bears an aryl substituent, or R^5 is joined together with R^6 as defined below;

wherein either R^6 is hydrogen, aryl or heterocyclic, or alkyl of up to 5 carbon atoms which is unsubstituted or which bears a hydroxy, aryl or heterocyclic substituent;
15

or R^6 and R^5 are joined together to form alkylene or alkenylene of 2 to 5 carbon atoms; or an oxa, thia or aza-derivative of said alkylene or alkenylene; or a hydroxy- or oxo-substituted derivative
20 of said alkylene or alkenylene; or R^6 and R^{16} , or R^6 , R^{16} and R^5 , or R^6 and R^{10} are joined together as defined below;

wherein R^{16} is hydrogen or alkyl of up to 5 carbon atoms;

25 or R^6 and R^{16} are joined together to form alkylene of 2 to 5 carbon atoms (that is, to form a spirocycloalkyl group);

or R^{16} together with the first carbon atom of R^6 form a double bond wherein R^6 is otherwise alkyl,
30 or wherein R^6 is otherwise substituted alkyl as defined above, or wherein R^6 and R^5 are otherwise joined together as defined above (that is, so that R^5 , R^6 and R^{16} together form alkylidene);

wherein Q is carbonyl (-CO-) or methylene (-CH₂-);

and wherein either R¹⁰ is hydroxy, amino, aryloxy, arylthio, alkoxy, cycloalkoxy, alkylamino, dialkylamino, cyclic amino, hydroxyalkoxy, acyloxyalkoxy, aminoalkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, cyclic aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, dialkylaminoalkylamino, cyclic aminoalkylamino or aryl-alkoxy wherein each alkyl or alkoxy has up to 5 carbon atoms and wherein cyclic amino has up to 6 carbon atoms; or wherein R¹⁰ and R⁶ are joined together such that R¹⁰ is oxygen (-O-) joined to the terminal carbon atom of R⁶ when it is alkyl;

wherein R¹¹ is hydrogen or alkyl of up to 3 carbon atoms;

wherein X is carbonyl (-CO-), hydroxymethylene (-CHOH-), thiocarbonyl (-CS-) or oximinomethylene (-C=N-OR²⁰ wherein R²⁰ is hydrogen or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent); and wherein Y is carbonyl, thiocarbonyl, sulphonyl (-SO₂-) or amido (-NHCO-);

or a salt thereof where appropriate, characterised by either:

(a) the reaction of an acid of the formula:-




wherein R¹, R², R³, R⁴, R¹¹, X and Y have the meanings stated above, or of a reactive derivative thereof, with an amine of the formula:-




wherein R⁵, R⁶, R¹⁶ and Q have the meanings stated above

and wherein R^{12} has any of the meanings stated above for R^{10} except those containing a free hydroxy or amino group; or

- (b) for the manufacture of an amide derivative
 5 wherein R^2 is hydrogen and X is carbonyl or thiocarbonyl, the reaction of an amine of the formula:




- wherein R^3 , R^4 , R^5 , R^6 , R^{11} , R^{12} , R^{16} and have the meanings stated above and X^1 is carbonyl or thiocarbonyl,
 10 with a compound of the formula R^1-Y-Z^1 , wherein R^1 and Y have the meanings stated above and wherein Z^1 is a displaceable halogen, alkanesulphonyl or arensulphonyl group, or Z^1 is hydroxy (in which case the reaction is carried out in the presence of a carbodiimide or an
 15 alkyl chloroformate), or, when Y is amido, with a compound of the formula R^1NCO , or, when Y is thiocarbonyl, with a compound of the formula $R^1CS-SCH_2COOH$; or
 (c) for the manufacture of an amide derivative
 wherein R^2 is hydrogen and X is a carbonyl, the reaction
 20 of a compound of the formula:-




wherein R^4 , R^5 , R^6 , R^{11} , R^{12} , R^{16} , and Q have the meanings stated above and Z^2 is a displaceable halogen atom, with a compound of the formula

25



wherein R^1 and R^3 have the meanings stated above,
followed by hydrolysis of the oxazolone ring;
whereafter an amide derivative wherein R^2 is alkyl,
arylalkyl or aryl (and R^{10} is R^{12}) may be obtained by
5 reacting the corresponding amide derivative wherein R^2
is hydrogen (and R^{10} is R^{12}) with a compound of the
formula R^2Z , wherein R^2 has the meaning stated above and
 Z is a displaceable halogen, alkanesulphonyl or
arenesulphonyl group;
10 or whereafter an amide derivative wherein R^3 is
unsubstituted or substituted alkyl may be obtained by
the hydrogenation of the corresponding compound wherein
 R^3 is unsubstituted or substituted alkenyl;
or whereafter an amide derivative wherein R^{10} is other
15 than hydroxy (that is, wherein $-Q-R^{10}$ forms an ester or
amide group) may be obtained from the corresponding
acid wherein $-Q-R^{10}$ is $-COOH$ by conventional means of
ester or amide formation;
or whereafter an amide derivative wherein Q is carbonyl
20 and R^{10} is hydroxy may be obtained by the hydrolysis
of the corresponding amide derivative wherein R^{10} is
alkoxy, or, when R^{10} is *t*-butoxy, by the acid-catalysed
cleavage of said compound;
or whereafter an amide derivative wherein X is hydroxy-
25 methylene may be obtained by the reduction of the
corresponding amide derivative wherein X is carbonyl;
or whereafter an amide derivative wherein X is oximino-
methylene may be obtained by the reaction of the
corresponding amide derivative wherein X is carbonyl
30 with hydroxylamine or an *O*-substituted hydroxylamine
derivative.


2. A process for the manufacture of an amide
derivative having the formula:-




- wherein R^1 is alkyl of up to 15 carbon atoms which is, unsubstituted or which bears an aryl, aryloxy or arylthio substituent, or R^1 is aryl or aryloxy, or R^1 is a substituent of the formula $\text{R}^8\text{CONHCHR}^9\text{-}$ or $\text{R}^8\text{COCH}_2\text{CHR}^9\text{-}$ wherein R^8 is alkyl or cycloalkyl each of up to 10 carbon atoms, or aryl, and R^9 is hydrogen, or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, or R^9 is a group other than those stated above such that the compound $\text{H}_2\text{NCHR}^9\text{COOH}$ would be a common amino acid;
- wherein Y and R^2 have the meanings stated in claim 1;
- wherein R^3 is alkyl or alkenyl each of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent; or R^3 is aryl or indolylmethyl;
- wherein X is carbonyl, hydroxymethylene, thiocarbonyl or oximinomethylene (C=N-OH);
- wherein R^4 is hydrogen or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent;
- wherein either R^5 is hydrogen, aryl or alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl substituent, R^6 is hydrogen, alkyl of up to 5 carbon atoms which is unsubstituted or which bears an aryl or heterocyclic substituent, or R^6 is heterocyclic or aryl, and R^{16} is hydrogen;
- or R^5 and R^6 are joined together to form alkylene or alkenylene of 2 to 4 carbon atoms; or an oxa, thia or aza-derivative of said alkylene or alkenylene;

or R^6 , R^{16} and R^5 are joined together such that R^{16} together with the first carbon atom of R^6 form a double bond wherein R^6 and R^5 are otherwise joined together as defined above;

- 5 and wherein R^7 is hydrogen or alkyl of up to 5 carbon atoms; or a salt thereof, characterised by the reaction of an acid of the formula:-




- 10 wherein R^1 , R^2 , R^3 , R^4 , X and Y have the meanings stated above, or of a reactive derivative thereof, with an amine of the formula:-



- wherein R^5 , R^6 and R^{16} have the meanings stated above and wherein R^{12} is alkyl of up to 5 carbon atoms;
- 15 whereafter an amide derivative wherein R^2 is alkyl, arylalkyl or aryl (and R^7 is alkyl) may be obtained by reacting the corresponding amide derivative wherein R^2 is hydrogen (and R^7 is alkyl) with a compound of the formula R^2Z , wherein R^2 has the meaning stated
- 20 above and Z is a displaceable halogen, alkanesulphonyl or arenesulphonyl group;
- or whereafter an amide derivative wherein R^7 is hydrogen may be obtained by the hydrolysis of the corresponding amide derivative wherein R^7 is alkyl, or, when R^7 is
- 25 t-butyl, by the acid-catalysed cleavage of said compound;
- or whereafter an amide derivative wherein X is hydroxy-methylene may be obtained by the reduction of the corresponding amide derivative wherein X is carbonyl;
- 30 or whereafter an amide derivative wherein X is oximino-methylene may be obtained by the reaction of the

corresponding amide derivative wherein X is carbonyl with hydroxylamine.


3. A process for the manufacture of an amide derivative having the formula:-



- wherein R^1 is methyl, benzyl, β -phenylethyl, benzyloxy, phoxymethyl, phenylthiomethyl, phenyl, tolyl, methoxyphenyl, methylthiophenyl, monochlorophenyl, dichlorophenyl, trifluoromethylphenyl, acetamidophenyl, 10 acetylphenyl, methanesulphonylphenyl, biphenyl, naphthyl, benzamidomethyl, cyclopentanecarbonamidomethyl or β -benzoylethyl;
 R^3 is benzyl which is unsubstituted or bears a methyl, t-butyl, methoxy, fluoro, chloro, bromo, nitro, cyano, 15 trifluoromethyl, amino, acetamido, methanesulphonamido, trifluoromethanesulphonamido or phenyl substituent, or R^3 is 3-phenylpropyl or 3-phenylprop-2-enyl;
 R^4 is hydrogen or methyl;
 R^5 is hydrogen or methyl and R^6 is hydrogen, benzyl or 20 indol-3-ylmethyl, or R^5 and R^6 together form trimethylene, tetramethylene, pentamethylene, 2-hydroxytrimethylene, 2-thiatrimethylene, 3-thiatetramethylene, 3-oxatetramethylene, 3-methyl-3-azatetramethylene; and
 R^{10} is hydroxy, amino, alkoxy of up to 5 carbon atoms, 25 or β -dimethylaminoethoxy or β -morpholinoethoxy; or a salt thereof, characterised by
 (a) the reaction of an acid of the formula:-




wherein R^1 , R^3 and R^4 have the meanings stated above, 30 or of a reactive derivative thereof, with an amine of the formula:-



wherein R^5 and R^6 have the meanings stated above and wherein R^{12} has any of the meanings stated above for R^{10} except hydroxy and amino; or

(b) the reaction of an amine of the formula:-




wherein R^3 , R^4 , R^5 , R^6 and R^{12} have the meanings stated above, with a compound of the formula R^1-COZ^1 , wherein R^1 has the meaning stated above and wherein Z^1 is a displaceable halogen, alkanesulphonyl or aren-sulphonyl group, or Z^1 is hydroxy (in which case the reaction is carried out in the presence of a carbodi-imide or an alkyl chloroformate); or

(c) the reaction of a compound of the formula:-



15 wherein R^4 , R^5 , R^6 and R^{12} have the meanings stated above and Z^2 is a displaceable halogen atom, with a compound of the formula:



wherein R^1 and R^3 have the meanings stated above,
 20 followed by hydrolysis of the oxazolone ring;
 whereafter an amide derivative wherein R^3 is 3-phenyl-propyl may be obtained by the hydrogenation of the corresponding compound wherein R^3 is 3-phenylprop-2-enyl;
 whereafter an amide derivative wherein R^{10} is hydroxy
 25 may be obtained by the hydrolysis of the corresponding amide derivative wherein R^{10} is alkoxy, or, when R^{10} is t-butoxy, by the acid-catalysed cleavage of said compound;

and whereafter an amide derivative wherein R^{10} is other than hydroxy (that is, wherein COR^{10} forms an ester or amide group) may be obtained from the corresponding acid wherein $-CO-R^{10}$ is $-COOH$ by conventional means of ester or amide formation.

4. A process as claimed in claim 3 wherein in the starting materials R^1 is phenyl, p-acetamidophenyl or p-cyanophenyl, R^3 is benzyl, p-methylbenzyl or p-methoxybenzyl, R^4 is hydrogen or methyl, R^5 and R^6 are joined together to form trimethylene and R^{10} is hydroxy, amino, methoxy, ethoxy, isopropyl or t-butoxy.

PH 31443/31584

RPS/MJW : 14 Jul 81

R. P. Slatcher

REGINALD PETER SLATCHER

AUTHOR'S REPRESENTATIVE
No. 97



European Patent
Office

EUROPEAN SEARCH REPORT

0045161
Application number

EP 81 30 3270

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P	FR - A - 2 340 933 (E.R. SQUIBB AND SONS) * Claims *	1,5,10	C 07 C 103/50 103/84 C 07 D 207/16 277/06 279/06 265/06 239/04 307/32 209/20
	--		
	US - A - 3 526 663 (D.P. HABIB) * Columns 1,2 *	1,3,4	
	--		
	EP - A - 0 010 347 (AMERICAN CYANAMID CO.) * Claims *	1,5,10	
	--		
	GB - A - 2 028 794 (GRISSMAN CHEM. LTD.) * Page 1 *	1	C 07 C 103/50 103/84 C 07 D 207/16 277/06 279/06 265/06 239/04 307/32 209/20
	--		
	EP - A - 0 021 883 (MERRELL TORANDE et CO.) * Claims *	1,5,10	

			TECHNICAL FIELDS SEARCHED (Int. Cl.)
			C 07 C 103/50 103/84 C 07 D 207/16 277/06 279/06 265/06 239/04 307/32 209/20
			CATEGORY OF CITED DOCUMENTS
			X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons
			&: member of the same patent family. corresponding document
<div style="display: flex; justify-content: space-between;"> <div> <p><input checked="" type="checkbox"/> The present search report has been drawn up for all claims</p> </div> </div>			
Place of search	Date of completion of the search	Examiner	
The Hague	06-10-1981	BRIGHENTI	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.